US20030049274A1 - PRRSV vaccines - Google Patents
PRRSV vaccines Download PDFInfo
- Publication number
- US20030049274A1 US20030049274A1 US09/948,747 US94874701A US2003049274A1 US 20030049274 A1 US20030049274 A1 US 20030049274A1 US 94874701 A US94874701 A US 94874701A US 2003049274 A1 US2003049274 A1 US 2003049274A1
- Authority
- US
- United States
- Prior art keywords
- prrsv
- replicon
- nucleic acid
- protein
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 34
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 title claims description 187
- 241000700605 Viruses Species 0.000 claims abstract description 111
- 230000010076 replication Effects 0.000 claims abstract description 50
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 46
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 43
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 43
- 238000001727 in vivo Methods 0.000 claims abstract description 11
- 244000005700 microbiome Species 0.000 claims abstract description 8
- 230000000241 respiratory effect Effects 0.000 claims abstract description 8
- 230000001850 reproductive effect Effects 0.000 claims abstract description 5
- 101710141454 Nucleoprotein Proteins 0.000 claims description 91
- 235000001014 amino acid Nutrition 0.000 claims description 39
- 150000001413 amino acids Chemical class 0.000 claims description 37
- 101710110895 Uncharacterized 7.3 kDa protein in cox-rep intergenic region Proteins 0.000 claims description 36
- 239000012634 fragment Substances 0.000 claims description 30
- 241000282887 Suidae Species 0.000 claims description 27
- 230000015572 biosynthetic process Effects 0.000 claims description 23
- 239000003550 marker Substances 0.000 claims description 21
- 101150082475 ORF7 gene Proteins 0.000 claims description 20
- 238000012986 modification Methods 0.000 claims description 20
- 230000004048 modification Effects 0.000 claims description 20
- 210000000234 capsid Anatomy 0.000 claims description 17
- 239000002773 nucleotide Substances 0.000 claims description 17
- 125000003729 nucleotide group Chemical group 0.000 claims description 17
- 101710085938 Matrix protein Proteins 0.000 claims description 16
- 101710127721 Membrane protein Proteins 0.000 claims description 16
- 241000710788 Lelystad virus Species 0.000 claims description 10
- 239000012528 membrane Substances 0.000 claims description 10
- 210000002845 virion Anatomy 0.000 claims description 9
- 230000001018 virulence Effects 0.000 claims description 8
- 108091092724 Noncoding DNA Proteins 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 101000765604 Bacillus subtilis (strain 168) FlaA locus 22.9 kDa protein Proteins 0.000 claims description 4
- 101000964402 Caldicellulosiruptor saccharolyticus Uncharacterized protein in xynC 3'region Proteins 0.000 claims description 4
- 101000977779 Lymantria dispar multicapsid nuclear polyhedrosis virus Uncharacterized 33.9 kDa protein in PE 3'region Proteins 0.000 claims description 4
- 101000827630 Narcissus mosaic virus Uncharacterized 10 kDa protein Proteins 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 101150001779 ORF1a gene Proteins 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 102100032965 Myomesin-2 Human genes 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims description 2
- 230000000405 serological effect Effects 0.000 claims description 2
- 229940024606 amino acid Drugs 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101000977065 Acidithiobacillus ferridurans Uncharacterized 11.6 kDa protein in mobS 3'region Proteins 0.000 claims 1
- 101000861180 Cupriavidus necator (strain ATCC 17699 / DSM 428 / KCTC 22496 / NCIMB 10442 / H16 / Stanier 337) Uncharacterized protein H16_B0147 Proteins 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 238000009877 rendering Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 62
- 230000002458 infectious effect Effects 0.000 abstract description 55
- 238000003556 assay Methods 0.000 abstract description 3
- 208000011580 syndromic disease Diseases 0.000 abstract description 2
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 abstract 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 67
- 210000004027 cell Anatomy 0.000 description 67
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 43
- 230000035772 mutation Effects 0.000 description 39
- 239000002299 complementary DNA Substances 0.000 description 37
- 108090000623 proteins and genes Proteins 0.000 description 31
- 108020004414 DNA Proteins 0.000 description 26
- 101710172711 Structural protein Proteins 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 26
- 238000004519 manufacturing process Methods 0.000 description 23
- 230000037430 deletion Effects 0.000 description 22
- 238000012217 deletion Methods 0.000 description 22
- 239000000427 antigen Substances 0.000 description 21
- 108091007433 antigens Proteins 0.000 description 21
- 102000036639 antigens Human genes 0.000 description 21
- 238000002703 mutagenesis Methods 0.000 description 20
- 108091027544 Subgenomic mRNA Proteins 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 18
- 108700026244 Open Reading Frames Proteins 0.000 description 17
- 238000011999 immunoperoxidase monolayer assay Methods 0.000 description 17
- 239000002245 particle Substances 0.000 description 17
- 101800001494 Protease 2A Proteins 0.000 description 16
- 210000002540 macrophage Anatomy 0.000 description 16
- 231100000350 mutagenesis Toxicity 0.000 description 16
- 244000052769 pathogen Species 0.000 description 16
- 239000013598 vector Substances 0.000 description 16
- 101710087110 ORF6 protein Proteins 0.000 description 14
- 101710095001 Uncharacterized protein in nifU 5'region Proteins 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 230000000890 antigenic effect Effects 0.000 description 13
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 12
- 108020000999 Viral RNA Proteins 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 description 9
- 241001493065 dsRNA viruses Species 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 241000711573 Coronaviridae Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 241000710803 Equine arteritis virus Species 0.000 description 5
- 241000710789 Lactate dehydrogenase-elevating virus Species 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 101000621943 Acholeplasma phage L2 Probable integrase/recombinase Proteins 0.000 description 4
- 101000618348 Allochromatium vinosum (strain ATCC 17899 / DSM 180 / NBRC 103801 / NCIMB 10441 / D) Uncharacterized protein Alvin_0065 Proteins 0.000 description 4
- 101000781117 Autographa californica nuclear polyhedrosis virus Uncharacterized 12.4 kDa protein in CTL-LEF2 intergenic region Proteins 0.000 description 4
- 101000708323 Azospirillum brasilense Uncharacterized 28.8 kDa protein in nifR3-like 5'region Proteins 0.000 description 4
- 101000770311 Azotobacter chroococcum mcd 1 Uncharacterized 19.8 kDa protein in nifW 5'region Proteins 0.000 description 4
- 101000748761 Bacillus subtilis (strain 168) Uncharacterized MFS-type transporter YcxA Proteins 0.000 description 4
- 101000765620 Bacillus subtilis (strain 168) Uncharacterized protein YlxP Proteins 0.000 description 4
- 101000916134 Bacillus subtilis (strain 168) Uncharacterized protein YqxJ Proteins 0.000 description 4
- 101000754349 Bordetella pertussis (strain Tohama I / ATCC BAA-589 / NCTC 13251) UPF0065 protein BP0148 Proteins 0.000 description 4
- 101000827633 Caldicellulosiruptor sp. (strain Rt8B.4) Uncharacterized 23.9 kDa protein in xynA 3'region Proteins 0.000 description 4
- 101000947628 Claviceps purpurea Uncharacterized 11.8 kDa protein Proteins 0.000 description 4
- 101000686796 Clostridium perfringens Replication protein Proteins 0.000 description 4
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 101000788129 Escherichia coli Uncharacterized protein in sul1 3'region Proteins 0.000 description 4
- 101000788370 Escherichia phage P2 Uncharacterized 12.9 kDa protein in GpA 3'region Proteins 0.000 description 4
- 101000787096 Geobacillus stearothermophilus Uncharacterized protein in gldA 3'region Proteins 0.000 description 4
- 101000976889 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 19.2 kDa protein in cox-rep intergenic region Proteins 0.000 description 4
- 101000827627 Klebsiella pneumoniae Putative low molecular weight protein-tyrosine-phosphatase Proteins 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 101001130841 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF5 Proteins 0.000 description 4
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 description 4
- 108010076039 Polyproteins Proteins 0.000 description 4
- 101710130262 Probable Vpr-like protein Proteins 0.000 description 4
- 101000974028 Rhizobium leguminosarum bv. viciae (strain 3841) Putative cystathionine beta-lyase Proteins 0.000 description 4
- 101000756519 Rhodobacter capsulatus (strain ATCC BAA-309 / NBRC 16581 / SB1003) Uncharacterized protein RCAP_rcc00048 Proteins 0.000 description 4
- 101000948219 Rhodococcus erythropolis Uncharacterized 11.5 kDa protein in thcD 3'region Proteins 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 101000936711 Streptococcus gordonii Accessory secretory protein Asp4 Proteins 0.000 description 4
- 101000929863 Streptomyces cinnamonensis Monensin polyketide synthase putative ketoacyl reductase Proteins 0.000 description 4
- 101000788468 Streptomyces coelicolor Uncharacterized protein in mprR 3'region Proteins 0.000 description 4
- 101000845085 Streptomyces violaceoruber Granaticin polyketide synthase putative ketoacyl reductase 1 Proteins 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- 101000711771 Thiocystis violacea Uncharacterized 76.5 kDa protein in phbC 3'region Proteins 0.000 description 4
- 101000711318 Vibrio alginolyticus Uncharacterized 11.6 kDa protein in scrR 3'region Proteins 0.000 description 4
- 108010067390 Viral Proteins Proteins 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 230000003362 replicative effect Effects 0.000 description 4
- 230000007480 spreading Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 101000768957 Acholeplasma phage L2 Uncharacterized 37.2 kDa protein Proteins 0.000 description 3
- 101000823746 Acidianus ambivalens Uncharacterized 17.7 kDa protein in bps2 3'region Proteins 0.000 description 3
- 101000916369 Acidianus ambivalens Uncharacterized protein in sor 5'region Proteins 0.000 description 3
- 101000769342 Acinetobacter guillouiae Uncharacterized protein in rpoN-murA intergenic region Proteins 0.000 description 3
- 101000823696 Actinobacillus pleuropneumoniae Uncharacterized glycosyltransferase in aroQ 3'region Proteins 0.000 description 3
- 101000786513 Agrobacterium tumefaciens (strain 15955) Uncharacterized protein outside the virF region Proteins 0.000 description 3
- 101000618005 Alkalihalobacillus pseudofirmus (strain ATCC BAA-2126 / JCM 17055 / OF4) Uncharacterized protein BpOF4_00885 Proteins 0.000 description 3
- 102100020724 Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Human genes 0.000 description 3
- 101000967489 Azorhizobium caulinodans (strain ATCC 43989 / DSM 5975 / JCM 20966 / LMG 6465 / NBRC 14845 / NCIMB 13405 / ORS 571) Uncharacterized protein AZC_3924 Proteins 0.000 description 3
- 101000823761 Bacillus licheniformis Uncharacterized 9.4 kDa protein in flaL 3'region Proteins 0.000 description 3
- 101000819719 Bacillus methanolicus Uncharacterized N-acetyltransferase in lysA 3'region Proteins 0.000 description 3
- 101000789586 Bacillus subtilis (strain 168) UPF0702 transmembrane protein YkjA Proteins 0.000 description 3
- 101000792624 Bacillus subtilis (strain 168) Uncharacterized protein YbxH Proteins 0.000 description 3
- 101000790792 Bacillus subtilis (strain 168) Uncharacterized protein YckC Proteins 0.000 description 3
- 101000819705 Bacillus subtilis (strain 168) Uncharacterized protein YlxR Proteins 0.000 description 3
- 101000948218 Bacillus subtilis (strain 168) Uncharacterized protein YtxJ Proteins 0.000 description 3
- 101000718627 Bacillus thuringiensis subsp. kurstaki Putative RNA polymerase sigma-G factor Proteins 0.000 description 3
- 101000641200 Bombyx mori densovirus Putative non-structural protein Proteins 0.000 description 3
- 101000947633 Claviceps purpurea Uncharacterized 13.8 kDa protein Proteins 0.000 description 3
- 101000948901 Enterobacteria phage T4 Uncharacterized 16.0 kDa protein in segB-ipI intergenic region Proteins 0.000 description 3
- 101000805958 Equine herpesvirus 4 (strain 1942) Virion protein US10 homolog Proteins 0.000 description 3
- 101000790442 Escherichia coli Insertion element IS2 uncharacterized 11.1 kDa protein Proteins 0.000 description 3
- 101000788354 Escherichia phage P2 Uncharacterized 8.2 kDa protein in gpA 5'region Proteins 0.000 description 3
- 101000770304 Frankia alni UPF0460 protein in nifX-nifW intergenic region Proteins 0.000 description 3
- 101000797344 Geobacillus stearothermophilus Putative tRNA (cytidine(34)-2'-O)-methyltransferase Proteins 0.000 description 3
- 101000748410 Geobacillus stearothermophilus Uncharacterized protein in fumA 3'region Proteins 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 101000772675 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) UPF0438 protein HI_0847 Proteins 0.000 description 3
- 101000631019 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Uncharacterized protein HI_0350 Proteins 0.000 description 3
- 101000768938 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 8.9 kDa protein in int-C1 intergenic region Proteins 0.000 description 3
- 101000785414 Homo sapiens Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Proteins 0.000 description 3
- 101000782488 Junonia coenia densovirus (isolate pBRJ/1990) Putative non-structural protein NS2 Proteins 0.000 description 3
- 101000811523 Klebsiella pneumoniae Uncharacterized 55.8 kDa protein in cps region Proteins 0.000 description 3
- 101000818409 Lactococcus lactis subsp. lactis Uncharacterized HTH-type transcriptional regulator in lacX 3'region Proteins 0.000 description 3
- 101000878851 Leptolyngbya boryana Putative Fe(2+) transport protein A Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101000758828 Methanosarcina barkeri (strain Fusaro / DSM 804) Uncharacterized protein Mbar_A1602 Proteins 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 101001122401 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF3 Proteins 0.000 description 3
- 101001055788 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) Pentapeptide repeat protein MfpA Proteins 0.000 description 3
- 241001292005 Nidovirales Species 0.000 description 3
- 101000740670 Orgyia pseudotsugata multicapsid polyhedrosis virus Protein C42 Proteins 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 101000769182 Photorhabdus luminescens Uncharacterized protein in pnp 3'region Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 101000961392 Pseudescherichia vulneris Uncharacterized 29.9 kDa protein in crtE 3'region Proteins 0.000 description 3
- 101000731030 Pseudomonas oleovorans Poly(3-hydroxyalkanoate) polymerase 2 Proteins 0.000 description 3
- 101001065485 Pseudomonas putida Probable fatty acid methyltransferase Proteins 0.000 description 3
- 230000006819 RNA synthesis Effects 0.000 description 3
- 101000711023 Rhizobium leguminosarum bv. trifolii Uncharacterized protein in tfuA 3'region Proteins 0.000 description 3
- 101000948156 Rhodococcus erythropolis Uncharacterized 47.3 kDa protein in thcA 5'region Proteins 0.000 description 3
- 101000917565 Rhodococcus fascians Uncharacterized 33.6 kDa protein in fasciation locus Proteins 0.000 description 3
- 101000790284 Saimiriine herpesvirus 2 (strain 488) Uncharacterized 9.5 kDa protein in DHFR 3'region Proteins 0.000 description 3
- 101000936719 Streptococcus gordonii Accessory Sec system protein Asp3 Proteins 0.000 description 3
- 101000788499 Streptomyces coelicolor Uncharacterized oxidoreductase in mprA 5'region Proteins 0.000 description 3
- 101001102841 Streptomyces griseus Purine nucleoside phosphorylase ORF3 Proteins 0.000 description 3
- 101000708557 Streptomyces lincolnensis Uncharacterized 17.2 kDa protein in melC2-rnhH intergenic region Proteins 0.000 description 3
- 101000649826 Thermotoga neapolitana Putative anti-sigma factor antagonist TM1081 homolog Proteins 0.000 description 3
- 101000827562 Vibrio alginolyticus Uncharacterized protein in proC 3'region Proteins 0.000 description 3
- 101000778915 Vibrio parahaemolyticus serotype O3:K6 (strain RIMD 2210633) Uncharacterized membrane protein VP2115 Proteins 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000037797 influenza A Diseases 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 101000653197 Beet necrotic yellow vein virus (isolate Japan/S) Movement protein TGB3 Proteins 0.000 description 2
- 102100031725 Cortactin-binding protein 2 Human genes 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 2
- 241000712431 Influenza A virus Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 101800000933 Non-structural protein 10 Proteins 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 101710197985 Probable protein Rev Proteins 0.000 description 2
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- 101000714195 Varicella-zoster virus (strain Dumas) Tegument protein UL51 homolog Proteins 0.000 description 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
- 210000001132 alveolar macrophage Anatomy 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000012252 genetic analysis Methods 0.000 description 2
- 108010070825 hemagglutinin-protease Proteins 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- SEEYREPSKCQBBF-UHFFFAOYSA-N n-methylmaleimide Chemical compound CN1C(=O)C=CC1=O SEEYREPSKCQBBF-UHFFFAOYSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229940124551 recombinant vaccine Drugs 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229940126580 vector vaccine Drugs 0.000 description 2
- 101710194912 18 kDa protein Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101000787133 Acidithiobacillus ferridurans Uncharacterized 12.3 kDa protein in mobL 3'region Proteins 0.000 description 1
- 101000787132 Acidithiobacillus ferridurans Uncharacterized 8.2 kDa protein in mobL 3'region Proteins 0.000 description 1
- 101000827262 Acidithiobacillus ferrooxidans Uncharacterized 18.9 kDa protein in mobE 3'region Proteins 0.000 description 1
- KXEVYGKATAMXJJ-ACZMJKKPSA-N Ala-Glu-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O KXEVYGKATAMXJJ-ACZMJKKPSA-N 0.000 description 1
- CJQAEJMHBAOQHA-DLOVCJGASA-N Ala-Phe-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)N)C(=O)O)N CJQAEJMHBAOQHA-DLOVCJGASA-N 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 101000811747 Antithamnion sp. UPF0051 protein in atpA 3'region Proteins 0.000 description 1
- GBSUGIXJAAKZOW-GMOBBJLQSA-N Asp-Ile-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O GBSUGIXJAAKZOW-GMOBBJLQSA-N 0.000 description 1
- 101000977023 Azospirillum brasilense Uncharacterized 17.8 kDa protein in nodG 5'region Proteins 0.000 description 1
- 101000827603 Bacillus phage SPP1 Uncharacterized 10.2 kDa protein in GP2-GP6 intergenic region Proteins 0.000 description 1
- 101000827607 Bacillus phage SPP1 Uncharacterized 8.5 kDa protein in GP2-GP6 intergenic region Proteins 0.000 description 1
- 101000961975 Bacillus thuringiensis Uncharacterized 13.4 kDa protein Proteins 0.000 description 1
- 101000961984 Bacillus thuringiensis Uncharacterized 30.3 kDa protein Proteins 0.000 description 1
- 101000964407 Caldicellulosiruptor saccharolyticus Uncharacterized 10.7 kDa protein in xynB 3'region Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000710777 Classical swine fever virus Species 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 101000644901 Drosophila melanogaster Putative 115 kDa protein in type-1 retrotransposable element R1DM Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101000747702 Enterobacteria phage N4 Uncharacterized protein Gp2 Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 101710124086 Envelope protein UL45 Proteins 0.000 description 1
- 101000758599 Escherichia coli Uncharacterized 14.7 kDa protein Proteins 0.000 description 1
- VSXBYIJUAXPAAL-WDSKDSINSA-N Gln-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O VSXBYIJUAXPAAL-WDSKDSINSA-N 0.000 description 1
- HHQCBFGKQDMWSP-GUBZILKMSA-N Gln-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)N)N HHQCBFGKQDMWSP-GUBZILKMSA-N 0.000 description 1
- XFAUJGNLHIGXET-AVGNSLFASA-N Gln-Leu-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O XFAUJGNLHIGXET-AVGNSLFASA-N 0.000 description 1
- 101000768777 Haloferax lucentense (strain DSM 14919 / JCM 9276 / NCIMB 13854 / Aa 2.2) Uncharacterized 50.6 kDa protein in the 5'region of gyrA and gyrB Proteins 0.000 description 1
- 101800003471 Helicase Proteins 0.000 description 1
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 1
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 1
- 101100462341 Homo sapiens OSBPL2 gene Proteins 0.000 description 1
- 101710126256 Hydrolase in agr operon Proteins 0.000 description 1
- RQJUKVXWAKJDBW-SVSWQMSJSA-N Ile-Ser-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N RQJUKVXWAKJDBW-SVSWQMSJSA-N 0.000 description 1
- 101000607404 Infectious laryngotracheitis virus (strain Thorne V882) Protein UL24 homolog Proteins 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 101710125507 Integrase/recombinase Proteins 0.000 description 1
- 102100024407 Jouberin Human genes 0.000 description 1
- 101000735632 Klebsiella pneumoniae Uncharacterized 8.8 kDa protein in aacA4 3'region Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 101000768930 Lactococcus lactis subsp. cremoris Uncharacterized protein in pepC 5'region Proteins 0.000 description 1
- 101000976302 Leptospira interrogans Uncharacterized protein in sph 3'region Proteins 0.000 description 1
- 101000778886 Leptospira interrogans serogroup Icterohaemorrhagiae serovar Lai (strain 56601) Uncharacterized protein LA_2151 Proteins 0.000 description 1
- 101000977786 Lymantria dispar multicapsid nuclear polyhedrosis virus Uncharacterized 9.7 kDa protein in PE 3'region Proteins 0.000 description 1
- 101710141347 Major envelope glycoprotein Proteins 0.000 description 1
- 101100285000 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) his-3 gene Proteins 0.000 description 1
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 1
- 101800000932 Non-structural protein 11 Proteins 0.000 description 1
- 101800000511 Non-structural protein 2 Proteins 0.000 description 1
- 101800000514 Non-structural protein 4 Proteins 0.000 description 1
- 101800000482 Non-structural protein 9 Proteins 0.000 description 1
- 102100025925 Oxysterol-binding protein-related protein 2 Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001123971 Porcine reproductive and respiratory syndrome virus 1 Species 0.000 description 1
- VOZIBWWZSBIXQN-SRVKXCTJSA-N Pro-Glu-Lys Chemical compound NCCCC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1)C(O)=O VOZIBWWZSBIXQN-SRVKXCTJSA-N 0.000 description 1
- XQHGISDMVBTGAL-ULQDDVLXSA-N Pro-His-Phe Chemical compound C([C@@H](C(=O)[O-])NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1[NH2+]CCC1)C1=CC=CC=C1 XQHGISDMVBTGAL-ULQDDVLXSA-N 0.000 description 1
- FMLRRBDLBJLJIK-DCAQKATOSA-N Pro-Leu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FMLRRBDLBJLJIK-DCAQKATOSA-N 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108090000944 RNA Helicases Proteins 0.000 description 1
- 102000004409 RNA Helicases Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101710200092 Replicase polyprotein Proteins 0.000 description 1
- 101001121571 Rice tungro bacilliform virus (isolate Philippines) Protein P2 Proteins 0.000 description 1
- 101001113905 Rice tungro bacilliform virus (isolate Philippines) Protein P4 Proteins 0.000 description 1
- 101100518421 Schizosaccharomyces pombe (strain 972 / ATCC 24843) orc2 gene Proteins 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- 241001516645 Simian hemorrhagic fever virus Species 0.000 description 1
- 101000818100 Spirochaeta aurantia Uncharacterized 12.7 kDa protein in trpE 5'region Proteins 0.000 description 1
- 101000818098 Spirochaeta aurantia Uncharacterized protein in trpE 3'region Proteins 0.000 description 1
- 101001026590 Streptomyces cinnamonensis Putative polyketide beta-ketoacyl synthase 2 Proteins 0.000 description 1
- 101001037658 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) Glucokinase Proteins 0.000 description 1
- 101000750896 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized protein Synpcc7942_2318 Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 241000711517 Torovirus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 101000916321 Xenopus laevis Transposon TX1 uncharacterized 149 kDa protein Proteins 0.000 description 1
- 101100261632 Zea mays TSB2 gene Proteins 0.000 description 1
- 101000760088 Zymomonas mobilis subsp. mobilis (strain ATCC 10988 / DSM 424 / LMG 404 / NCIMB 8938 / NRRL B-806 / ZM1) 20.9 kDa protein Proteins 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002089 crippling effect Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 244000309457 enveloped RNA virus Species 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000001466 metabolic labeling Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- -1 nucleoside triphosphate Chemical class 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 208000009305 pseudorabies Diseases 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10041—Use of virus, viral particle or viral elements as a vector
- C12N2770/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10061—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
- The invention relates to the field of PRRS viruses and infectious clones obtained from PRRS viruses. Furthermore, the invention relates to vaccines and diagnostic assays obtainable by using and modifying such infectious clones of PRRS viruses.
- Porcine reproductive and respiratory syndrome virus (PRRSV) is a positive-strand RNA virus that belongs to the family of arteriviruses together with equine arteritis virus (EAV), lactate dehydrogenase-elevating virus (LDV) and simian hemorrhagic fever virus (Meulenberg et al., 1993). Recently, the International Committee on the Taxonomy of Viruses has decided to incorporate this family in a new order of viruses, the Nidovirales, together with the Coronaviridae (genomic length 28 to 30 kb), and Toroviridae (genomic length 26 to 28 kb). The order Nidovirales represents enveloped RNA viruses that contain a positive-stranded RNA genome and synthesize a 3′ nested set of subgenomic RNAs during replication. The subgenomic RNAs of coronaviruses and arteriviruses contain a leader sequence which is derived from the 5′ end of the viral genome. The subgenomic RNAs of toroviruses lack a leader sequence. Whereas the ORFs 1a and 1b, encoding the RNA dependent RNA polymerase, are expressed from the genomic RNA, the smaller ORFs at the 3′ end of the genomes of Nidovirales, encoding structural proteins, are expressed from the subgenomic mRNAs.
- A replicon herein is defined as derived from a recombinant nucleic acid. Although genomic information regarding PRRSV is now emerging, it is for example not known where deletions or modifications in the PRRSV genome can be located so that the resulting recombinant nucleic acid can be used as a functional replicon allowing in vivo RNA replication, be it in (complementary) cells expressing essential (PRRS) viral proteins (such as polymerase or structural (envelope) proteins or not, or allowing independent in vivo RNA replication in animals, such as pigs, after vaccination with a vaccine comprising a nucleic acid encoding such a PRRS replicon.
- PRRSV (Lelystad virus) was first isolated in 1991 by Wensvoort et al. (1991) and was shown to be the causative agent of a new disease now known as porcine reproductive respiratory syndrome (PRRS). The main symptoms of the disease are respiratory problems in pigs and abortions in sows, sometimes complicated by sow-mortality. Although the major outbreaks, such as observed at first in the US in 1987 and in Europe in 1991, have diminished, this virus, in its various virulent or less-virulent forms, still causes major economic losses in herds in the US, Europe, and Asia.
- PRRSV preferentially grows in alveolar lung macrophages (Wensvoort et al., 1991). A few cell lines, such as CL2621 and other cell lines cloned from the monkey kidney cell line MA-104 are also susceptible to the virus. Some well known PRRSV strains are known under accession numbers CNCM I-1102, I-1140, I-1387, I-1388, ECACC V93070108, or ATCC VR 2332, VR 2385, VR 2386, VR 2429, VR 2474, and VR 2402. The genome of PRRSV is 15 kb in length and contains genes encoding the RNA dependent RNA polymerase (ORF1a and ORF1b) and genes encoding structural proteins (
ORFs 2 to 7; Meulenberg et al., 1993 and Meulenberg et al., 1996). ORF5 encodes the major envelope glycoprotein, designated GP5. TheORFs - Pigs can be infected by PRRSV via the oronasal route. Virus in the lungs is taken up by lung alveolar macrophages and in these cells replication of PRRSV is completed within 9 hours. PRRSV travels from the lungs to the lung lymphnodes within 12 hours and to peripheral lymphnodes, bone marrow and spleen within 3 days. At these sites, only a few cells stain positive for viral antigen. The virus is present in the blood during at least 21 days and often much longer. After 7 days antibodies to PRRSV are found in the blood. The combined presence of virus and antibody in PRRS infected pigs shows that the virus infection can persist for a long time, albeit at a low level, despite the presence of antibody. During at least 7 weeks the population of alveolar cells in the lungs is different from normal SPF lungs.
- PRRSV needs its envelope to infect pigs via the oronasal route and the normal immune response of the pig thus entails among others the production of neutralising antibodies directed against one or more of the envelope proteins; such antibodies can render the virus non-infective. However, once in the alveolar macrophage, the virus also produces naked capsids, constructed of RNA encapsidated by the M and/or N protein, sometimes partly containing any one of the glycoproteins. The intra- and extracellular presence of these incomplete viral particles or (partly) naked capsids can be demonstrated by electron microscopy. Sometimes, naked capsids without a nucleic acid content can be found. The naked capsids are distributed through the body by the bloodstream and are taken up from the blood by macrophages in spleen, lymphnodes and bonemarrow. These naked but infectious viral capsids can not be neutralised by the antibodies generated by the pig and thus explain the persistence of the viral infection in the presence of antibody. In this way, the macrophage progeny from infected bonemarrow cells is spreading the virus infection to new sites of the body. Because not all bonemarrow macrophage-lineage cells are infected, only a small number of macrophages at peripheral sites are infected and produce virus. PRRSV capsids, consisting of ORF7 proteins only, can be formed in the absence of other viral proteins, by for instance infection of macrophages with a recombinant pseudorabies-ORF7 vector virus. The PRV virus was manipulated to contain ORF7 genetic information of PRRSV. After 18 hours post infection, the cytoplasm of infected cells contains large numbers of small, empty spherical structures with the size of PRRS virus nucleocapsids.
- Although live-attenuated and killed PRRSV vaccines are now available, it has been shown that in general these are not immunogenic enough or are too virulent for specific groups of pigs, i.e. for young piglets or sows in the third trimester of pregnancy. It is clear that a PRRSV vaccine that is not sufficiently immunogenic will not stand up in the market. However, several of the existing immunogenic vaccines are not safe illustrating the need for attenuated PRRSV vaccines with reduced virulence.
- Furthermore, again under specific circumstances, several of the existing vaccines spread within a population, and may inadvertently infect other pigs that need not or should not be vaccinated, illustrating the need for non-spreading PRRSV vaccines.
- Furthermore, the existing vaccines can in general not be distinguished from wild type field virus, illustrating the need for a so-called marker vaccine, obtained for example by mutagenesis of the genome, so that vaccinated pigs can be distinghuished from field virus-infected pigs on the basis of differences in serum antibodies.
- In addition, PRRS vaccines, being so widely used throughout the world, and being in general not infectious to other animals but pigs, would be attractive candidate vaccines to carry foreign antigens derived from other (porcine) pathogens to provide for protection against those other pathogens, illustrating the need for PRRSV carrier or vector vaccines allowing vaccination against those other pathogens or allowing positive marker identification.
- It goes without saying, that PRRSV vaccines combining one or more of these features would be preferred. It is an object of the present invention to provide solutions to these needs.
- The invention provides a porcine reproductive and respiratory syndrome virus (PRRSV) replicon having at least some of its original PRRSV nucleic acid deletions, herein also comprising substitutions, said replicon capable of in vivo RNA replication, said replicon further having been deprived of at least some of its original PRRSV nucleic acid and/or having been supplemented with nucleic acid derived from a heterologous micro-organism.
- Surprisingly, it has been found that the genome of PRRSV can be deprived of quite a large amount of its nucleic acid. An independent and functional PRRSV replicon capable of independent in vivo RNA replication can still exist if the stretch, or fragments thereof, of nucleic acid encoding the ORF2-ORF6, but not an essential element from the ORF7 protein, is deleted and/or modified. Having a replicon wherein such a large stretch of nucleic acid has been deleted or modified opens up a large capacity for the addition to said replicon of heterologous nucleic acid from any other organism than PRRSV, thereby providing a PRRSV vector replicon with large carrier capacities. Herewith, the inventor provides identification of specific nucleic acid regions in the genome of porcine reproductive and respiratory syndrome virus, that are important for attenuation of the virus, for making it non- or little spreading or for the introduction of a marker, without crippling the viral nucleic acid so much that it can no longer provide in vivo RNA replication. Furthermore, the inventor demonstrates that a PRRSV replicon can be used as vector for the expression of foreign antigens, preferably derived from other (porcine) pathogens, allowing vaccination against those other pathogens and allowing positive marker identification. The minimal sequence requirements for a PRRSV replicon or PRRSV vector replicon as provided by the invention are essential elements comprising the 5′ noncoding region-ORF1a-ORF1b-ORF7-3′ noncoding region, (e.g. from the PRRSV polymerase region) whereby the ORF7 coding region can be deleted further for example according to the data shown in FIG. 2. In a preferred embodiment, the invention provides a PRRSV replicon or vector at least comprising essential elements from the PRRSV polymerase region for example as described below and/or comprising at least nucleic acid derived from a essential region of 44 nucleotides between nucleotides 14642 to 14686 in the ORF7 gene (as identified in the nucleic acid sequence of the Lelystad virus isolate of PRRSV, however, the skilled person can easily determine by alignment wherein in any other PRRSV genome said essential element is located).
- In another preferred embodiment, the invention provides a PRRSV replicon comprising at least nucleic acid derived from essential sequence elements from ORF1a and ORF1b, or from the PRRSV polymerase region and having nucleic acid from ORF2, ORF 3, ORF 4, ORF 5, ORF 6, or non-essential elements from ORF7 deleted, allowing insertion of foreign nucleic acid, thereby providing a PRRSV vector replicon having foreign antigen coding capacities. This in contrast to WO98/55626 where the homologous polymerase is replaced with a heterologous Arteriviral one to express ORF2-ORF7, essentially without disclosing expression of foreign antigens derived from other (porcine) pathogens to provide for protection against those other pathogens allowing vaccination against those other pathogens (let alone wherein the PRRSV genome nucleic acid encoding foreign antigens may be located for providing a PRRSV vector replicon or which essential sequence elements should remain).
- The replicase polyprotein of PRRSV encoded by ORF1 is thought to be cleaved in 13 processing end-products (designated nonstructural proteins—nsps) and a large number of intermediates. The polyprotein is cleaved by protease domains located in nsp1α, nsp1β, nsp2 and nsp4. Essential PRRSV RNA-dependent RNA polymerase and nucleoside triphosphate-binding/RNA Helicase motifs were identified in nsp9 and nsp10, respectively. Another conserved (essential) domain was found in nsp11, a conserved Cys/His-rich domain was found in nsp10. It has for example been shown that the latter protein plays a role in subgenomic mRNA synthesis.
- In a further embodiment, the invention provides a PRRSV replicon capable of independent in vivo RNA replication wherein said replicon is a RNA transcript of an infectious copy cDNA. It has been shown for many positive strand RNA viruses that their 5′ and/or 3′ noncoding regions contain essential signals that control the initiation of plus- and minus-strand RNA synthesis. It was not determined for PRRSV whether these sequences alone are sufficient for replication. As for most RNA viruses, PRRSV contains a concise genome and most of the genetic information is expected to be essential. Furthermore, the maximum capacity for the integration of foreign genes into the PRRSV genome is not yet known. An extra limitation is that the ORFs encoding the structural proteins of PRRSV are partially overlapping. The introduction of mutations in these overlapping regions often results in two mutant structural proteins and therefore is more often expected to produce a nonviable virus.
- The production of an infectious clone allowed us to analyse replication signals in the genome of PRRSV. In this study we have mapped cis-acting sequence elements required for replication by introducing deletions in the infectious clone. Surprisingly, we have shown that also cis-acting sequence elements from the region of the genome encoding structural proteins are essential for proper replication. We have shown that transcripts derived from cDNA clones lacking the ORF7 gene are not replicated. A more systematic deletion analysis showed that a region of 44 nucleotides between nucleotides 14642 to 14686 in the ORF7 gene was essential for replication of RNA of PRRS. This was an interesting finding, since the sequences essential for replication of most positive strand RNA viruses are present in the 5′ and 3′ noncoding regions. It is an important finding for studies who's aim is to develop viral replicons which can only be rescued in complementing cell lines expressing the deleted ORFs. The minimal sequence requirements for these RNAs are located in the 5′ noncoding region-ORF1a-ORF1b-ORF7-3′ noncoding region. Viral RNA's or replicons containing these sequence elements supplemented with a selection of fragments from other PRRSV open reading frames or fragments of open reading frames expressing antigens of other (heterologous) pathogens can be packaged into virus particles when the proteins essential for virus assembly are supplied in trans. When these particles are given to pigs, for example as vaccine, they will enter specific host cells such as macrophages and virus- or heterologous antigens are expressed and induce immune responses because of the replicating RNA. However, since the RNA does not express (all) the proteins required for packaging and the production of new particles, the replicon can not spread further, creating an extremely efficient, but safe and not-spreading recombinant vaccine effective against PRRSV and/or heterologous pathogens.
- In a preferred embodiment, the invention provides a replicon according to the invention incapable of N-protein capsid formation. For example, two Cys residues are present at positions 27 and 76 in the N protein sequence and mutating or deleting Cys-27 and Cys-76 from the N protein inhibits the production of infectious particles of PRRSV. The ORF7 gene encoding the N protein was mutated as such that the Cys residues were substituted for Asn and Leu residues, respectively, however, substitution with another amino acid, or deletion of the coding sequence, leads to the desired result as well, as for example can be seen below.
- The Cys-27 and Cys-76 mutations were subsequently introduced in the infectious clone pABV437 of the Lelystad virus isolate of PRRSV, resulting in plasmids pABV534-536 (Cys-27→Asn) and pABV472-475 (Cys-76→Leu). RNA was transcribed from these mutated infectious clones and transfected to BHK-21 cells. The structural proteins were properly expressed, these mutant RNAs were replicated and subgenomic RNAs synthesized. However, infectious particles were not secreted, since the transfer of the supernatant of the transfected BHK-21 cells to macrophages did not result in the production of viral proteins in the macrophages nor in the induction of a cpe.
- Thus, these residues are essential for a proper structure or function or both of the N protein in virus assembly of PRRSV. The N protein is involved in the first steps in virus assembly, the binding of the viral genomic RNA and formation of the capsid structure. Since transcripts of genomic length cDNA clones containing the Cys-27 and/or Cys-76 deletion replicated at the wild type level, the mutations in the Cys residues destroy the binding of the RNA by the N protein. Alternatively, they induce a different structure of the N protein that inhibits the formation of proper capsids. The defect in the encapsidation of the viral RNA genome can be complemented by wild type N protein transiently expressed or continuously expressed in a (BHK-21) cell line. In this way a virus is produced that is able to complete only one round of infection/replication. Therefore such a virus is considered to be a very safe vaccine for protection against PRRSV in pigs.
- In another example, the invention provides a replicon incapable of N-protein capsid formation wherein substitutions in the genome encoding the N protein area containing two antigenic regions designated B and D inhibited the production of infectious virus particles. The B region comprises amino acids 25-30 (QLCQLL), D region; amino acids 51-67 (PEKPHFPLAAEDDIRHH) and amino acids 80-90 (ISTAFNQGAGT) of the N protein of PRRSV. The corresponding sites in VR2332 and other American strains are found when the N proteins of these strains are aligned. Since RNA replication and subgenomic mRNA synthesis appeared to be at the wild type level, these mutations most likely prevented the formation of proper capsids by the N protein.
- The invention furthermore provides a replicon according to the invention wherein a marker allowing serological discrimination has been introduced. For example, mutagenesis of a single amino acid in the D region (Asp-62 or a.a. corresponding thereto) of protein N results in a replicon that has a different MAb binding profile from PRRSV and all other PRRSV viruses. Such a replicon induces a different spectrum of antibodies in pigs, compared to these other PRRSV isolates. Therefore it can be differentiated from field virus on the basis of serum antibodies and is an excellent mutant for further development of marker vaccines against PRRSV.
- The above example involves a subtle modification resulting in a replicon useful for a marker vaccine. However, more extensive changes are now also possible, knowing that it is allowed to partly or fully delete the nucleic acid encoding the
structural proteins - Furthermore, the invention provides a replicon comprising a nucleic acid modification in a virulence marker of PRRSV. Virulence markers of PRRSV have not been elucidated, despite the fact that various differences in virulence have been observed. However, for successfully attenuating a PRRSV or replicon thereof, such knowledge helps in selecting the least virulent, but most immunogenic replicon or virus possible. Now that it is known that deleting or modifying the ORF2 to
ORF 6 region is possible without effecting the in vivo RNA replicative properties, such virulence markers can easily be detected. For example, the invention provides replicon comprising a nucleic acid modification inORF 6 encoding the membrane spanning M-protein. It has been found that the membrane protein is influencing the virus assembly, the stability of the virus, or the virus entry in macrophages, all factors contributing to the virulence of PRRSV. The M protein is the most conserved structural protein among arteriviruses and coronaviruses. The protein is an integral membrane protein containing three N-terminal hydrophobic membrane spanning domains (Rottier, 1995). The protein spans the membrane three times leaving a short N-terminal domain outside the virion and a short C-terminal domain inside the virion. The M protein of coronaviruses was shown to play an important role in virus assembly (Vennema et al., 1996), but was then not determined to be a virulence factor. In particular, the invention provides a replicon wherein said modification modifies protein M in between its second and third membrane spanning fragment, essential in determining virulence of a specific PRRSV isolate. For example, the invention provides a replicon comprising vABV575. A Thr-59→Asn mutation is located between the second and third membrane spanning fragment of M in vABV575. This mutation influences virus assembly, the stability of the virus, or virus entry in the PAMs. - The invention furthermore provides a replicon according to the invention wherein said heterologous micro-organism comprises a pathogen. Since PRRSV specifically infects macrophages, it can be used as a vector for the delivery of important antigens of other (respiratory) agents to this specific cell of the immune system. The infectious cDNA clone enables us to introduce site specific mutations, deletions and insertions into the viral genome.
- In a preferred embodiment, the invention provides a replicon wherein said pathogen is a virus. We have successfully used PRRSV as a vector for the expression of a foreign protein anigen, an HA epitope of the haemagglutinin of influenza A virus. Recombinant PRRSV vector replicons were engineered that produced the HA tag fused to the N- or C-terminus of the N protein. In addition, an PRRSV mutant was created that contained the HA-tag as well as the protease 2A of foot-and-mouth-disease virus (FMDV) fused to the N terminus of the N protein.
- Furthermore, the invention provides a vaccine comprising a replicon or vector replicon according to the invention. PRRSV vaccines are now provided with specified antigenicity or immunogenicity that are in for example in addition safe enough for specific groups of pigs, i.e. for young piglets or sows in the third trimester of pregnancy.
- Furthermore, the invention provides non-spreading PRRSV vaccines, comprising a replicon or vector replicon for example incapable of N-protein capsid formation, or incapable of further infection due to the absence of (fragments of) structural proteins encoded by
ORF 2 to 6, without hampering its in vivo RNA replication properties, thereby allowing the production of proteins against which an immune response is desired. - Furthermore, the invention provides a vaccine that can be distinguished from wild type field virus, a so-called marker vaccine, obtained for example by mutagenesis of the genome, so that vaccinated pigs can be distinguished from field virus-infected pigs on the basis of differences in serum antibodies.
- In addition, PRRS vaccines, being so widely used throughout the world, and being in general not infectious to other animals but pigs, are now provided as vector vaccines to carry foreign antigens derived from other (porcine) pathogens, allowing vaccination against those other pathogens and allowing positive marker identification.
- Use of a vaccine according to the invention is especially useful for vaccinating pigs, sine the PRRSV is in general very host specific and replicates in macrophages of pigs, thereby targeting an important antigen presenting cell of the immune system.
- The invention is further explained in the detailed description, without limiting the invention.
- 1. Mutation of Cys-27 and Cys-76 in the N Protein Inhibits the Production of Infectious Particles of PRRSV
- The nucleocapsid protein N (expressed by ORF7) is present as a monomer in purified virions of PRRSV. However, in some experiments we also detected a homodimer of N. For instance when the N protein was immunoprecipitated from purified virions with N-specific MAbs and electrophorezed on a sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE), a protein of 15 kDa was predominantly observed under reduced conditions, whereas a homodimer of 30 kDa was predominantly observed under nonreduced conditions (Meulenberg et al., 1996). However, when compounds such as N-methyl maleimide or iodoacetamide were used to prevent the formation of nonspecific disulfide bonds, these dimers of N were not detected. This indicated that dimers of N are formed due to the formation of nonspecific disulfide bonds during the processing of cell lysates for analysis. Two cystein residues are present in the N protein sequence. The question raised which of the cysteine residues was responsible for the formation of nonspecific disulfide bonds and whether the cysteine residues are important for the structure and function of the N protein. To answer this question we mutated the two cystein residues individually in the infectious cDNA clone of PRRSV and studied the infectivity of the resulting mutant viral genomic RNAs.
- 2. Introduction of a Marker in the N Protein
- The N protein of PRRSV contains 4 antigenic sites, designated A-D (Meulenberg et al., 1998). Two sites, B and D, contain epitopes that are conserved in European and North American isolates of PRRSV. To produce viruses that can be serologically distinguished from wild type viruses, mutations in the B and D domain that disrupt the binding of N-specific MAbs were introduced in the infectious cDNA clone of PRRSV. Transcripts of the resulting mutant full length cDNA clones were analyzed for RNA replication by detecting the expression of structural proteins and production of infectious virus.
- 3. Elucidation of Replication Signals Present in the Region Encoding Structural Proteins of Lelystad Virus
- Positive strand RNA viruses contain 5′ and 3′ noncoding regions which are essential for replication. The RNA sequences at the 5′ and 3′ end usually have a specific secondary structure which is recognized by the viral RNA dependent RNA polymerase to initiate positive and negative strand synthesis and in the case of arteriviruses subgenomic RNA synthesis. We deleted the ORF7 gene from the infectious clone of PRRSV (Meulenberg et al., 1998) in a first attempt to generate a defective RNA replicon that could be complemented for production of infectious particles, when transfected to a cell expressing the N protein. The ORF7 gene was precisely deleted, without affecting the 3′ noncoding region of the virus. Surprisingly, the RNA of this deletion mutant did not replicate in BHK-21 cells. This suggested that RNA replication signals are present in the coding region of ORF7. The purpose of this study was to further localize these replication signals. By expensive deletion analysis of the coding region and upstream sequences of ORF7 we were able to identify a region of 44 nucleotides in the ORF7 gene that is important for replication of RNA of PRRSV.
- 4. Production of an Attenuated PRRSV Virus by Deletion of the NdeI Site in ORF6.
- Recently, we have established an infectious clone cDNA clone of PRRSV (Meulenberg et al., 1998). The full length cDNA clone contains two NdeI sites, the first at nucleotide 12559 (ORF3) and the second at nucleotide 14265 (in ORF6) in the genome sequence. To facilitate mutagenesis and exchange of fragments in the region encoding the structural proteins (
ORFs 2 to 7) of the virus, we destroyed the second NdeI site by PCR-directed mutagenesis. This resulted in an amino acid substitution atposition 59 in the M protein (Thr→Asn). The growth properties of the virus produced from the mutated full length cDNA clone containing a unique NdeI site was analysed. - 5. Lelystad Virus as a Vector for the Expression of Foreign Antigens or Proteins.
- The generation of an infectious cDNA clone of PRRSV (Meulenberg et al., 1998) is a major breakthrough in PRRSV research and opens up new possibilities for the development of new viral vectors. Since PRRSV specifically infects macrophages, it can be used as a vector for the delivery of important antigens of other (respiratory) agents to this specific cell of the immune system. The infectious cDNA clone enables us to introduce site specific mutations, deletions and insertions into the viral genome. However, it is still not known which regions of the PRRSV genome are essential or allow mutagenesis. As for most RNA viruses, PRRSV contains a concise genome and most of the genetic information is expected to be essential. Furthermore, the maximum capacity for the integration of foreign genes into the PRRSV genome is not yet known. An extra limitation is that the ORFs encoding the structural proteins of PRRSV are partially overlapping. The introduction of mutations in these overlapping regions results in two mutant structural proteins and therefore is more often expected to produce a nonviable virus.
- The aim of this study was to identify regions in the PRRSV genome that allow the introduction of foreign antigens that will be exposed to the immune system of the pig after infection with the mutant virus. In a first approach we have selected a small epitope of 9 amino acids of human haemagglutinin of influenza A for expression in PRRSV.
- METHODS
- Cells and Viruses
- BHK-21 cells were grown in BHK-21 medium (Gibco BRL), completed with 5% FBS, 10% tryptose phosphate broth (Gibco BRL), 20 mM Hepes pH 7.4 (Gibco BRL) and 200 mM glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin. Porcine alveolar lung macrophages (PAMs) were maintained in MCA-RPMI-1640 medium, containing 10% FBS, 100 μg/ml kanamycin, 200 U/ml penicillin and 200 μg/ml streptomycin. Virus stocks were produced by serial passage of recombinant PRRSV viruses secreted in the culture supernatant of tranfected BHK-21 cells on PAMs. Virus was harvested when PAMs displayed cytopathic effect (cpe) usually 48 hours after infection. Virus titers (expressed as 50% tissue culture infective doses [TCID50] per ml) were determined on PAMs using end point dilution (Wensvoort et al., 1986).
- Mutagenesis
- 1. Mutagenesis of Cys-27 and Cys-76.
- The Cys-27 was mutated to Asn by PCR-directed mutagenesis with primers LV108 and LV97. The sequences of primers used in this study are listed in Table 1 . The generated PCR fragment was digested with HpaI and PflmI and inserted in the ORF7 gene in pABV431 digested with the same enzymes. This resulted in plasmid pABV451 The Cys-76 was mutated to Leu by PCR-directed mutagenesis with primers LV108 and LV100. The generated fragment was digested with HpaI and ClaI and inserted in the ORF7 gene in pABV431 digested with the same enzymes. This resulted in pABV452. The mutated ORF7 genes were subsequently transferred to the genomic-length cDNA clone pABV437(Meulenberg et al., 1998) with the unique HpaI (nt 14581) and PacI (nt 14981) site, to create plasmids pABV534-536 (Cys-27→Asn) and plasmids pABV472-475 (Cys-76→Leu; FIG. 1).
- 2. Mutagenesis of Antigenic Site B and D in the N Protein
- Antigenic sites B (amino acids 25-30) and D (amino acids 51-67 and 80-90) of the N protein of PRRSV were mutated by substitution of the amino acids in this region for the corresponding amino acids of respectively EAV and LDV. Plasmids pABV455, pABV463, and pABV453 containing these respective mutation were described previously in Meulenberg et al. (1998). In addition, the Asp at position 62 in the D region of the N protein was mutated to a Tyr in a PCR with primers LV108 and LV188. The sequences of these primers are shown in Table 1. The PCR fragment was digested with HpaI and ClaI and inserted in the ORF7 gene in pABV431 digested with the same enzymes. This resulted in pABV582. The ORF7 genes containing the mutations were inserted in pABV437 using the unique HpaI (nt 14581) and PacI (nt 14981) (FIG. 1).
- 3: Creation of Deletion Mutants in the Full-Length cDNA Clone of PRRSV
- Several deletions were made in the full-length cDNA clone of pABV437 of PRRSV (FIG. 2). First, ORF2, ORF3, ORF4, ORF5 and the 5′ half of ORF6 were deleted. pABV437 was digested with EcoRI and NheI and the sites were made blunt with Klenow fragment (Pharmacia Biotech). The fragment was purified and ligated. This resulted in clone plasmid pABV594. Second, ORF7 was deleted from the infectious copy of PRRSV. For this purpose, the infectious full-length cDNA clone pABV442 that contains a SwaI restriction site directly downstream of the stopcodon of ORF7, was digested with HpaI and SwaI and ligated. This resulted in clone plasmid pABV521. Third, to delete the 3′ end of ORF6, PCR-mutagenesis was performed with primers LV198 and LV199. The primers used in PCR-mutagenesis are listed and described in Table 1. The generated product was digested with HpaI and NheI and ligated in the corresponding sites of pABV437. This resulted in plasmid pABV627. Fourth, several deletions in and upstream of the coding region of ORF7 were made. PCR-mutagenesis was performed with forward primers LV188-191 or LV195-197 and reversed primer LV112. The generated products were digested with HpaI and PacI and ligated in the same restriction sites of pABV437, resulting in plasmids pABV602-605 and pABV625-627. Plasmids were transformed to Escherichia coli DH5α and grown at 32° C. and 20 μg kanamycin per ml. For each construct two clones containing fragments of two independent PCRs were sequenced to confirm the correct sequence of the clones. The resultant mutants are shown in FIG. 2.
- 4. Mutagenesis of the NdeI Site at Position 14265 in the Infectious cDNA Clone pABV437 of PRRSV
- To mutate the NdeI site at position 14265 a fragment of 1.7 kb was amplified by PCR using primers LV27 (nt 12526) and LV182 (nt 14257; Table 1) Primer LV182 contains an AseI site. AseI and NdeI have compatible ends, but ligation of their ends to each other destroys both restriction sites. The PCR fragment was digested with NdeI and AseI and ligated in pABV437 digested with NdeI. The full length clone pABV575 (FIG. 3) that contained the PCR fragment in the proper orientation, lacked the NdeI site at position 14265 and had no other mutations between 12559 and 14265 due to PCR errors was selected for further analysis.
- 5: Construction of Full-Length Genomic cDNA Mutants of PRRSV Encoding an Antigenic HA tag
- PCR-mutagenesis was used to create mutants in the infectious clone of PRRSV. First, a sequence of 27 nucleotides encoding an epitope of the human haemagglutinin of influenza A (HA-tag; Kolodziej et al., 1991) was introduced directly downstream of the start codon of ORF7 in the PacI mutant of the genome-length cDNA clone of Lelystad Virus (pABV437; Meulenberg et al., 1998). Two sequential PCRs were performed with primers LV192 and LV112 and with primers LV193 and LV112. Primers used to create the PCR-fragments are listed and described in Table 1. Second, both this HA-tag and a sequence of 51 nucleotides encoding the protease 2A of FMDV (Percy et al., 1994) were introduced directly downstream of the startcodon of ORF7. Two sequential PCR-reactions were performed with primers LV139 and LV112 and with LV140 and LV112. Third, the HA-tag was introduced at the 31 end of the ORF7 gene in a PCR with primers LV108 and LV194. The three PCR fragments obtained were digested with HpaI and PacI and ligated into pABV437 digested with the same enzymes. Standard cloning procedures were performed essentially as described in Sambrook et al., (1989). Plasmids were transformed intoEscherichia coli DH5α and grown at 32° C. and 20 μg kanamycin per ml. For each construct two clones containing fragments of two independent PCRs were sequenced to confirm the correct sequence of the clones. Introduction of the HA epitope at the 5′ end of ORF7 resulted in the generation of clone pABV525, introduction of both the HA-tag and the protease 2A at the 5′ end of ORF7 resulted in clone pABV523, and the introduction of the HA-epitope at the 3′ end of ORF7 resulted in clone pABV526 (FIG. 4).
- Sequence Analysis
- The generated cDNA clones were analyzed by oligonucleotide sequencing. Oligonucleotide sequences were determined with the PRISM Ready Dye Deoxy Terminator cycle sequencing kit and the automatic sequencer (Applied Biosystems).
- In Vitro Transcription and Transfection of RNA
- Full-length genomic cDNA clones and derivatives thereof were linearized with PvuI, which is located directly downstream of the poly(A) stretch. The linearized plasmids were precipitated with ethanol and 1.5 μg of these plasmids was used for in vitro transcription with T7 RNA polymerase by the methods described for SFV by Liljeström and Garoff (1991). The in vitro transcribed RNA was precipitated with isopropanol, washed with 70% ethanol and stored at −20° C. until use.
- BHK-21 cells were seeded in 35-mm wells (approximately 106 cells/well) and were transfected with 2.5 μg in vitro transcribed RNA mixed with 10 ml lipofectin in optimem as described earlier (Meulenberg et al., 1998). Alternatively, RNA was introduced in BHK-21 cells in 20-mm wells with 0.5 μg in vitro transcribed RNA mixed with 2 ml lipofectin in optimem. The medium was harvested 24 h after transfection, and transferred to CL2621 cells or PAMs to rescue infectious virus. Transfected and infected cells were tested for expression of PRRSV proteins by an immunoperoxidase monolayer assay (IPMA), essentially as described by Wensvoort et al. (1986). Monoclonal antibodies (MAbs) 122.14, 122.1, and 126.3 directed against respectively the GP3, GP4, M protein (van Nieuwstadt et al., 1996) were used for staining in this assay. A panel of MAbs (122.17, 125.1, 126.9, 126.15, 130.2, 130.4, 131.7, 131.9, 138.22, WBE1, WBE4, WBE5, WBE6, SDOW17, NS95, and NS99) directed to four different antigenic sites A-D were used to study the expression of the N protein (Meulenberg et al., 1998). MAb 12CAS was used to detect the expression of the HA-epitope and was purchased from Boehringer Mannheim. In addition, we analyzed the expression of PRRSV proteins by metabolic labeling of transfected or infected cells, followed by immunoprecipitation using specific monoclonal antibodies or peptide sera directed to the structural proteins of PRRSV, as described by Meulenberg et al (1996).
- Sequence Analysis of Genomic RNA of Recombinant Viruses
- The culture supernatant of the PAMs infected with
passage 3 of the HA-expressing viruses was used to analyze viral RNA by RT-PCR. A volume of 500 μl proteinase K buffer (100 mM Tris-HCl [pH 7.2], 25 mM EDTA, 300 mM NaCl, 2% [wt/vol] sodium dodecyl sulfate) and 0.2 mg Proteinase K was added to 500 μl supernatant. After incubation for 30 minutes at 37° C., the RNA was extracted with phenol-chloroform and precipitated with ethanol. The RNA was reverse transcibed with primer LV76. Then, PCR was performed with primers LV37 and LV112 to amplify fragments of vABV523 and vABV525 and with primers LV37 and LV75 to amplify fragments of vABV526 (Table 1). Sequence analysis was performed to determine whether the mutant viruses atpassage 4 still contained the inserted foreign sequences. - Results
- 1. Mutation of Cys-27 and Cys-76 in full length cDNA clone pABV437 Two Cys residues are present at positions 27 and 76 in the N protein sequence. The ORF7 gene encoding the N protein was mutated as such that the Cys residues were substituted for Asn and Leu residues, respectively. The Cys-27 and Cys-76 mutations were subsequently introduced in the infectious clone pABV437 of the Lelystad virus isolate of PRRSV, resulting in plasmids pABV534-536 (Cys-27→Asn) and pABV472-475 (Cys-76→Leu; FIG. 1). RNA was transcribed from these mutated infectious clones and transfected to BHK-21 cells. These cells stained positive with N-specific MAbs in IPMA. Analysis of the N protein synthesized by pABV534-536 and pABV472-475 in immuno precipitation and SDS-PAGE indicated that its apparent molecular weight was similar to the wild type N protein and migrated at 15 kDa under reducing conditions. Next we analyzed the N protein under nonreducing conditions in the absence of N-methyl maleimide or iodoacetamide. Under these conditions, the N protein expressed by pABV472-475 (Cys-76→Leu) resembled the wild type N protein and was mainly detected as a dimer, whereas the N protein expressed by pABV534-536 (Cys-27→Asn) was detected as a monomer. This indicated that the Cys residue at position 27 was responsible for the formation of nonspecific disulfide bonds. The production of other structural proteins such as GP3, GP4, and M was also detected in IPMA and immuno precipitation after transfection of full length RNA from plasmids pABV534-536 (Cys-27→Asn) and pABV472-475 (Cys-76→Leu: FIG. 1). Since the structural proteins were properly expressed, these mutant RNAs were replicated and subgenomic RNAs synthesized. However, infectious particles were not secreted, since the transfer of the supernatant of the transfected BHK-21 cells to PAMs did not result in the production of viral proteins in the PAMs nor in the induction of a cpe. Therefore both Cys residues are essential for a proper structure or function or both of the N protein in virus assembly.
- 2. Characterization of Full Length cDNA Clones containing Mutations in Antigenic Sites of the N Protein of PRRSV
- Site B (amino acids 25-30) and D (amino acids 51-67 and 80-90) are two antigenic regions that are conserved in European and North American PRRSV isolates. When we mutated site B and D by substituting their amino acid sequence for the corresponding amino acids of the LDV or EAV N protein, the binding of the N protein by respectively B-specific and D-specfic MAbs was disrupted (Meulenberg et al., 1998). To produce a PRRSV virus that is antigenically different from PRRSV field viruses, we introduced the ORF7 genes containing a mutated B or D region in our infectious clone pABV437. This resulted in pABVS27-533, containing a mutated B site (amino acids 25-30), pABV537-539 containing a mutated D domain (amino acids 51-67), and pABV512-515 containing a mutated D domain (amino acids 80-90) (FIG. 1). When RNA of these full length clones was transfected to BHK-21 cells, these cells stained positive with N-specific MAbs at 24 h after transfection. As expected, the N protein expressed by pABV527-533 was recognized by A-, C-, and D-specific MAbs, but not by B-specific MAbs. On the other hand the N protein expressed by pABV537-539 and pABV512-515 was recognized by A-, B-, and C-specific MAbs but not by D-specific MAbs. The staining of cells transfected with the RNA derived from pABVS27-533 , pABV537-539 and pABV512-515 with MAbs directed against GP3, GP4, and M, was similar to that observed in transfections with RNA derived from wild type pABV437. This suggested that RNA replication and subgenomic mRNA synthesis were not affected by the mutations. When the supernatant of the cells transfected with RNA derived from pABV527-533, pABV537-539 and pABV512-515 was transferred to PAMs, cpe was not produced. Most likely, the mutations in the B and D region destroyed the function of the N protein in the formation of a proper capsid structure.
- Since the mutation of 4 amino acids in domain B and 5 or 9 amino acids in domain D did not allow the generation of infectious particles we then created a more subtle mutation of 1 amino acid in the D region. We introduced an Asp-62 to Tyr mutation in the N-protein in the infectious clone of PRRSV. The amino acid Asp-62 in the PRRSV N protein was mutated to Tyr by PCR directed mutagenesis and transferred to pABV437, resulting in pABV600. RNA transcribed from pABV600 was tranfected to BHK-21 cells. These cells stained positive with MAbs directed against GP3, GP4, M and N. At 24 h after transfection, suggesting that the RNA was replicated and subgenomic mRNAs were synthesized. When the supernatant of the BHK-21 cells transfected with transcripts from pABV600 was transferred to PAMs, cpe was detected at 2-3 days after inoculation. The infected cells stained positive with PRRSV specific MAbs, which further confirmed that infectious virus was produced. Therefore, the mutation of Asp-62 to Tyr in the N protein is tolerated in the virus and does not destroy the function of the N protein. The mutant virus VABV600 was further typed with a panel of N-specific MAbs (Table 2). Not only the binding of D-specific MAb SDOW17, but also the binding of D-specific MAbs 130.2, 130.4, 131.7, and 131.9 and WBE1 to vABV600 was greatly reduced. If hybridoma culture supernatant of these MAbs was diluted to 0.3-0.5 μg IgG/ml bright staining was observed for wild type PRRSV, but no staining could be observed for vABV600. However, when the IgG of MAbs 130.2, 130.4, 131.7, and 131.9 was purified and used more concentrated (10 μg IgG/ml) faint staining was observed. Staining of vABV600 with A- and B-specific MAbs was comparable to PRRSV. These data indicated that we have created a virus that is antigenically different from wild type PRRSV or North American PRRS viruses.
- 3: Identification of Replication Signals at the 3′ End of the PRRSV Genome
- In order to determine cis-acting sequences that are essential signals for RNA replication (plus and/or minus strand synthesis and/or subgenomic mRNA synthesis), several deletions were made in the infectious cDNA clone and transcripts derived from these deletion mutants were analysed for replication in BHK-21 cells. When transcripts from pABVS21, lacking the entire ORF7 gene were transfected to BHK-21 cells, the expression of the N-protein could not be detected in IPMA (FIG. 2). Interestingly, these transcripts were also defective in the expression of other structural proteins, such as GP3, GP4 and M. This indicated that these RNAs were not replicated and did not produce subgenomic RNAs. On the other hand, the deletion of ORF2, ORF3, ORF4, ORF5 and the 5′ end ORF6 from the infectious copy (pABV594) resulted in viral RNA that was still capable of replication. Therefore, replication signals are present in the coding region of ORF7 and not in the coding region of ORF's 2-6. To test this and further locate the regions involved in replication, mutants containing smaller deletions in ORF7 were constructed. The transcripts of these constructs were tested for their ability to replicate by detecting the expression of PRRSV proteins in IPMA of transfected BHK-cells (FIG. 2). From these results, it could be concluded that essential signals for replication of the PRRSV genome are present between nucleotides 14643 to 14687. Viral RNAs lacking this region were defective in replication.
- 4. Analysis of Full Length cDNA Clone pABV575 Lacking the NdeI Site in ORF6
- A full length cDNA clone, pABV575, was created that had a unique NdeI site at position 12559 due to mutation of the second NdeI site at position 14265 by PCR. RNA was produced from pABV575 and transfected to BHK-21 cells together with RNA from its parent clone pABV437. At 24 h after transfection with pABV575 RNA and pABV437 RNA an equal number of cells stained positive in IPMA with M-specific and N-specific MAbs (FIG. 3). Furthermore, the intensity of the staining was similar. However, when the supernatant of the transfected BHK-21 cells was transferred to PAMs and incubated for 24 h, the number of cells infected by vABV575 was much lower than that observed for vABV437. Furthermore, the cpe developed much slower in the PAMs inoculated with vABV575 than with vABV437. Although the replication of the RNA and synthesis of the subgenomic RNAs of vABV575 in BHK-21 appeared to be at the wild type level, the virus that is produced was less infectious for macrophages. This was most likely due to the amino acid mutation in the M protein (Thr→Asn) that resulted from the destruction of the NdeI site at position 14265.
- 5: Introduction of an HA-Tag in the Infectious Clone of PRRSV
- An epitope of the haemagglutinin of influenza A (HA-tag; Kolodziej et al., 1991) was expressed by different recombinant PRRSV viruses. The HA epitope was chosen as foreign antigen for expression in PRRSV mainly for two reasons; First, the tag has a limited size (27 nucleotides), which reduces the chance to disturb the replication of the virus or the expression or function of the protein to which it is fused. Second, antibodies to detect the expression of this epitope are available. The HA-tag was introduced at the 5′ end of ORF7 (pABV525), and at the 3′ end of ORF7 (pABV526; FIG. 4) as such that it did not induce mutations in other ORFs. We expected to get high expression of the foreign antigen by inserting it in the ORF7 gene, because subgenomic messenger RNA7(encoding ORF7) is most abundantly produced in infected cells. Since we could not predict the influence of the HA-epitope on the function and the structure of the N protein, we created an additional in frame insertion of the 16-amino acid self-cleaving 2A protease of foot-and-mouth disease virus (FMDV; Percy et al., 1994). This protease was introduced downstream of the HA-tag at the 5′ end of ORF7, which resulted in clone pABV523 (FIG. 4). We expected that this would result in the expression of a polyprotein, which could be proteolytically cleaved to release both the HA-tag and the N-protein.
- 5. Analysis of Recombinants of PRRSV Expressing the HA Epitope
- First, the expression of the structural proteins by the various transcripts from the recombinant full-length cDNA clones was tested in IPMA. BHK-21 cells, transfected with transcripts of pABV523, 525, and 526 stained positive with MAbs directed against GP3, GP4, the M protein, and the N protein, which indicated that these PRRSV proteins were properly expressed (FIG. 4). The cells also stained positive with a MAb directed against HA, indicating that the HA epitope was expressed by all three RNAs. Therefore, the HA-expressing transcripts replicated in BHK-21 cells. In addition, the N-protein to which the HA-tag was fused was still expressed by the mutant RNAs.
- To examine whether the transcripts of pABV523, 525 and 526 were able to produce infectious virus, the culture supernatant of transfected BHK-21 cells was used to infect PAMs.
- PAMs not only stained positive with MAbs directed against the PRRSV proteins GP3, GP4, M protein and N protein in IPMA, but also with MAb 12CA5 directed against the HA epitope. However, when PAMs were double stained, both with MAbs against the HA-tag and the N protein, we also detected PAMs which could only be stained with the MAb against the N protein but not with that against the HA-tag. For viruses derived from pABV525 and pABV526 the percentage of cells that stained only with N-specific Mabs was higher than for the viruses derived form pABV523, which contained the additional protease 2A. This indicated that the HA-tag directly attached to the N- or C-terminus of the N protein disturbed to some extent either the packaging of the viral RNA or the infectivity of the virus. However, when the protease 2A was introduced to cleave the HA-tag from the N protein by the protease 2A, the fitness of the resulting virus (vABV523) was not or hardly reduced (FIG. 4). The recombinant viruses were designated vABV523, vABV525 and vABV526.
- Analysis of protease 2A activity in vABV523 The activity of the protease 2A was further analyzed by radioimmunoprecipitation. Besides a 15 kDa protein, an additional protein of approximately 18 kDa was immunoprecipitated with N-specific MAb 122.17 from cells transfected with transcripts of pABV523. The 15 kDa protein was similar in size to the wild type N protein; the 18 kDa protein resembled the expected size of the polyprotein of HA-protease 2A-N. These data indicated that protease 2A of FMDV is able to cleave the HA-protease 2A-N polyprotein in the cell, which results in the release of the HA-tag from the N protein.
- 5.Growth Characteristics of HA-Expressing Viruses
- The amount of virus produced by BKH-21 cells transfected with transcripts from pABV437 and pABV523 was generally higher than that produced by BHK-21 cells transfected with transcripts from pABV525 and pABV526.
- Serial passage of HA-expressing viruses on PAMs resulted in stocks of vABV523, vABV525, and vABV526 with titers of approximately 107 TCID50/ml. It needs to be resolved whether the HA-expressing viruses have the same growth properties as the wild type virus of the infectious copy of PRRSV (vABV437). This will be studied in growth curves.
- 5. Analysis of the Stability of HA-Expressing Viruses.
- To determine the stability of HA-expressing viruses, viral RNA was examined at
passage 4. For this purpose, RT-PCR was performed on isolated viral RNA. Part of the ORF7 gene, the site at which the HA-tag was inserted, was amplified by PCR and the obtained fragments were analyzed on agarose gel. We obtained two fragments for vABV523 and vABV525 and one fragment for vABV526. Sequence analysis of the most abundantly amplified fragment showed that vABV523 atpassage 4 still contained the properly inserted nucleotide sequence encoding the HA-tag and the protease 2A gene. In contrast, both vABV525 and vABV526 had lost the inserted nucleotide sequence encoding the HA-tag. - 1. Mutation of Cys-27 and Cys-76 in the N Protein Inhibits the Production of Infectious Particles of PRRSV
- In this study we have found that mutation of Cys-27→Asn and Cys-76→Leu in the N protein of PRRSV interferes with the production of infectious particles in BHK-21 cells. We conclude that these residues are essential for a proper structure or function or both of the N protein in virus assembly of PRRSV. The N protein is involved in the first steps in virus assembly, the binding of the viral genomic RNA and formation of the capsid structure. Since transcripts of genomic length cDNA clones containing the Cys-27→Asn and Cys-76→Leu replicated at the wild type level, the mutations in the Cys residues destroy the binding of the RNA by the N protein. Alternatively, they induce a different structure of the N protein that inhibits the formation of proper capsids. The defect in the encapsidation of the viral RNA genome can be complemented by wild type N protein transiently expressed or continuously expressed in a (BHK-21) cell line. In this way a virus is produced that is able to complete only one round of infection/replication. Therefore such a virus is considered to be a very safe vaccine for protection against PRRSV in pigs.
- 2. Introduction of a Marker in the N Protein of PRRSV.
- The aim of this study was to create mutant PRRS viruses that can be serologically differentiated from field virus and therefore may be promising mutants for marker vaccine development against PRRSV. The N protein was chosen as a first candidate for mutagenesis to create a virus with a serologic marker since many studies have shown that the N protein is the most antigenic protein of PRRSV. For example, pigs infected with PRRSV develop strong antibody responses against the N protein of PRRSV (Meulenberg et al., 1995). In addition, the N protein contains two antigenic regions designated B and D that are conserved in European and US PRRSV isolates and MAbs directed to these regions are available (Meulenberg. et al., 1998). Here, we have demonstrated that mutation of 4 amino acids in site B to corresponding amino acids of the EAV N protein and mutation of 5 or 9 amino acids in domain D to corresponding amino acids of the LDV N protein inhibited the production of infectious virus particles. Since RNA replication and subgenomic mRNA synthesis appeared to be at the wild type level, these mutations most likely prevented the formation of proper capsids by the N protein. However, mutagenesis of a single amino acid in the D region (Asp-62→Tyr) resulted in virus vABV600 that had a different MAb binding profile from PRRSV and all other PRRSV Viruses. vABV600 induces a different spectrum of antibodies in pigs, compared to these other PRRSV isolates. Therefore vABV600 can be differentiated from field virus on the basis of serum antibodies and is an excellent mutant for further development of marker vaccines against PRRSV.
- 3: Elucidation of Replication Signals in ORF7 of Lelystad Virus
- It has been shown for many positive strand RNA viruses that their 5′ and/or 3′ noncoding regions contain essential signals that control the initiation of plus- and minus-strand RNA synthesis. It was not yet determined for PRRSV whether these sequences alone are sufficient for replication. The production of an infectious clone allowed us to analyse replication signals in the genome of PRRSV. In this study we have mapped cis-acting sequence elements required for replication by introducing deletions in the infectious clone. We have shown that transcripts derived from cDNA clones lacking the ORF7 gene are not replicated. A more systematic deletion analysis showed that a region of 44 nucleotides between nucleotides 14644 to 14687 in the ORF7 gene was important for replication of RNA of PRRSV. This was an essential interesting finding, since the sequences essential for replication of most positive strand RNA viruses are present in the 5′ and 3′ noncoding regions. It is also an important finding for studies who's aim is to develop viral replicons which can only be rescued in complementing cell lines expressing the deleted ORFs. The minimal sequence requirements for these RNAs are 5′ noncoding region-ORF1a-ORF1b-ORF7-3′ noncoding region. Viral RNA s or replicons containing these sequence elements supplemented with a selection of fragments from other PRRSV open reading frames or fragments of open reading frames expressing antigens of other (heterologous) pathogens can be packaged into virus particles when the proteins essential for virus assembly are supplied in trans. When these particles are given to pigs, for example as vaccine, they will enter specific host cells such as macrophages and virus- or heterologous antigens are expressed and induce immune responses because of the replicating RNA. However, since the RNA does not express (all) the proteins required for packaging and the production of new particles, the replicon can not spread further, creating an extremely efficient, but safe and not-spreading recombinant vaccine effective against PRRSV and/or heterologous pathogens.
- 4. Production of an Attenuated PRRSV Virus by Deletion of the NdeI Site in ORF6.
- In this study we have produced a mutant PRRS virus vABV575 that had different growth characteristics in PAMs compared to the parent strain vABV437. Whereas no difference in the expression of structural proteins in BHK-21 cells by RNAs of vABV575 or vABV437 was observed, the vABV575 virus produced in BHK-21 cells infected PAMs slower than vABV437. The growth kinetics of vABV575 need to be analyzed further by performing growth curves in PAMs. In the cDNA clone pABV575, that was used to produce vABV575, the NdeI site at position 14265 in ORF6 was mutated. This resulted in an amino acid change of Thr-59->Asn in the M protein. The mutated M protein was still bound by M-specific MAb 126.3. The M protein is the most conserved structural protein among arteriviruses and coronaviruses. The protein is an integral membrane protein containing three N-terminal hydrophobic membrane spanning domains (Rottier, 1995). The protein spans the membrane three times leaving a short N-terminal domain outside the virion and a short C-terminal domain inside the virion. The M protein of coronaviruses was shown to play an important role in virus assembly (Vennema et al., 1996). The Thr-59→Asn mutation is located between the second and third membrane spanning fragment of M in AB575. This mutation influences virus assembly, the stability of the virus, or virus entry in the PAMs.
- 5. Expression of the HA Epitope in Recombinant PRRSV viruses
- In this study we have successfully used PRRSV as a vector for the expression of a foreign antigen, an HA epitope of the haemagglutinin of influenza A virus. Recombinant PRRSV viruses were engineered that produced the HA tag fused to the N- or C- terminus of the N protein. In addition, a PRRSV mutant was created that contained the HA-tag as well as the protease 2A of FMDV fused to the N terminus of the N protein. The protease 2A was functionally active in the context of the PRRSV virus, and cleaved the HA-tag from the N protein. This resulted in an N protein that is identical to the wild type N protein, except for the first and second amino acids (Met and Ala) that are lacking in the mutant. Genetic analysis of
passage 4 of the recombinant viruses indicated that the mutant virus containing both the HA-tag and the protease 2A was more stable than the mutant viruses expressing the HA-N-fusion proteins. Apparently, the lack of the first methionine? and mutation of the second amino acid at the N-terminus of N is better tolerated by the virus than the addition of the HA-tag of 9 amino acids to the N- or C-terminus of N. Further genetic and functional analysis needs to be done to explain the differences in stability observed for these viruses. In addition, pigs need to be infected with these HA-expressing mutants to determine whether antibody responses are induced against the HA epitope. - The ORF7 gene was selected for insertion of the HA-tag mainly for two reasons; (I) The subgenomic RNA7 expressing this gene is the most abundant subgenomic RNA produced in infected cells and (II) the HA-tag could be inserted without mutating other ORFs since ORF7 has very little overlap with ORF6 at the 5′ end and no overlap with other ORFs at the 3′ end. However, similar constructs can be made by introducing the HA-tag and protease 2A at the 5′ end of ORP2 and at the 5′ end of ORF5 without affecting other ORFs.
- The successful expression of the HA-tag in combination with the protease 2A at the 5′ end of ORF7 creates new opportunities to express other foreign antigens such as the E2 protein of hog cholera virus, or B cell epitopes of parvo virus by PRRSV. Since PRRSV specifically infects macrophages, cells of the immune system that have antigen presentation and processing capacities, PRRSV might be an excellent vector for the expression of antigens and induction of immunity to these antigens in the pig.
- FIG. 1. Properties of full length cDNA clones of PRRSV containing mutations in the ORF7 gene. The mutated ORF7 genes were inserted in infectious cDNA clone pABV437 with the unique HpaI and PacI site that are indicated. The plasmid (pABV) numbers of the resulting constructs are shown. RNA replication was determined by detecting the expression of structural proteins in IPMA after transfection of the transcripts of the full length cDNA clones in BHK-21 cells. N protein production was determined in IPMA or immunoprecipitation. Production of infectious virus was established by transfer of the supernatant of transfected BHK-21 cells to PAMs and detection of cpe.
- FIG. 2. Properties of full length cDNA clones of PRRSV containing deletions in the region encoding the structural proteins of LV in order to elucidate the presence of replication signals in this region. The deleted regions (dotted bars), the regions of ORF7 still present (dark bars) and the plasmid (pABV) numbers of the resulting clones are shown. RNA replication was determined by detecting the expression of structural proteins, and the expression of the N-protein in particular, both in IPMA. Production of infectious virus was established by infecting PAMs with the supernatant of transfected BHK-21 cells. IPMA was performed to detect the expression of LV-proteins.
- FIG. 3. Properties of infectious cDNA clone pABV575. This clone was constructed by mutation of the NdeI site at position 14265 in ORF6. RNA replication was determined by detecting the expression of structural proteins in IPMA after transfection of the transcripts of the full length cDNA clones in BHK-21 cells. Production of infectious virus was established by transfer of the supernatant of transfected BHK-21 cells to PAMs and detection of cpe.
- FIG. 4. Introduction of an antigenic marker in the infectious clone of PRRSV. The insertion of the HA tag and protease 2A sequence in
plasmids pABV - 1. Liljeström, P. and Garoff, H. (1991). A new generation of animal cell expression vectors based on the Semliki Forest virus replicon.Biotechnol. 9, 1356-1361.
- 2. Kolodziej, P. A. and Young, R. A. Epitope tagging and protein surveillance. 1991.Methods Enzymol. 194, 508-519
- 3. Meulenberg, J. J. M., Bende, R. J., Pol, J. M., Wensvoort, G., and Moormann, R. J. M. (1995). Nucleocapsid protein N of Lelystad virus: expression by recombinant baculovirus, immunological properties, and suitability for detection of serum antibodies.Clin. Diagn. Laboratory Immunol. 2, 652-656.
- 4. Meulenberg, J. J. M., Hulst, M. M., de Meijer, E. J., Moonen, P. L. J. M., den Besten, A., de Kluyver, E. P., Wensvoort, G., and Moormann, R. J. M. (1993). Lelystad virus, the causative agent of porcine epidemic abortion and respiratory syndrome (PEARS) is related to LDV and EAV.Virology 192, 62-74.
- 5. Meulenberg, J. J. M., and Petersen-den Besten, A. (1996). Identification and characterization of a sixth structural protein of Lelystad virus: The glycoprotein GP2 encoded by ORF2 is incorporated in virus particles. Virology 225, 44-51.
- 6. Meulenberg, J. J. M., Bos-de Ruijter, J. N. A, van de Graaf, R., and Wensvoort, G., and R. J. M. Moormann. (1998) Infectious transcripts from cloned genome-length cDNA of porcine reproductive and respiratory syndrome virus. J. ofVirology 72, 380-387.
- 7. Meulenberg, J. J. M., van Nieuwstadt, A. P., van Essen-Zandbergen, A., Bos-de Ruijter, J. N. A., Langeveld, J. P. M., and Meloen, R. H. (1998) Localization and fine mapping of antigenic sites on the nucleocapsid protein N of porcine reproductive and respiratory syndrome virus with monoclonal antibodies.Virology, 252, 106-114.
- 8. Murtaugh, M. P., Elam, M. R., and Kakach, L. T., (1995). Comparison of the structural protein coding sequences of the VR-2332 and Lelystad virus strains of the PRRS virus.Arch. Virol. 140, 1451-1460.
- 9. Percy, N., Barclay, W. S., Garcia-Sastre, A. and Palese, P. Expression of a foreign protein by influenza A virus. 1994. J. Virol. 68: 4486-4492
- 10. Rottier, P. J. M. (1995) The coronavirus membrane protein, p. 115-139. In: S. D. Siddell (ed.), The coronaviridae. Plenum Press, New York, N.Y.
- 11. Sambrook, J., Fritsch, E. F. and Maniatis, T. Molecular cloning a laboratory manual. 1989. 2nd edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
- 12. van Nieuwstadt, A. P., Meulenberg, J. J. M., van Essen-Zandbergen, A., Petersen-den Besten, A., Bende, R. J., Moormann, R. J. M., and Wensvoort, G. (1996). Proteins encoded by
ORFs - 13. Wensvoort, G., Terpstra, C., Pol, J. M. A., Ter Laak, E. A., Bloemraad, M., de Kluyver, E. P., Kragten, C., van Buiten, L., den Besten, A., Wagenaar, F., Broekhuijsen, J. M., Moonen, P. L. J. M., Zetstra, T., de Boer, E. A., Tibben, H. J., de Jong, M. F., van't Veld, P., Groenland, G. J. R., van Gennep, J. A., Voets, M. Th., Verheijden, J. H. M., and Braamskamp, J. (1991). Mystery swine disease in the Netherlands: the isolation of Lelystad virus.Vet. Quart. 13, 121-130.
- 14. Vennema, H., Godeke, G. -J., Rossen, J. W. A., Voorhout, W. F., Horzinek, M. C., Opstelten, D. -J. E., and Rottier, P. J. M. (1996) Nucleocapsid-independent assembly of coronavirus-like patricales by viral envelope protein genes.EMBO J. 15, 2020-2028
- Wensvoort, G., Terpstra, C., Boonstra, J., Bloemraad, M., and van Zaane, D. (1986). Production of monoclonal antibodies against swine fever virus and their use in laboratory diagnosis. Vet. Microbiol. 12, 101-108.
TABLE 1 Primers used in PCR-mutagenesis and sequencing Sense (+) Primer (nt.) Sequence primera antisense(-) Purpose LV97 5′CATTGCACCCAGCAACGGTTCAGTTGT 3′ − Cys-27→Asn LV100 5′CGTCTGGATCGATTGCAAGAGGAGGGA 3′ − Cys-76→Leu LV188 5′TCTGGATCGATTGCAAGCAGAGGGAGCGTTCAGTCTGGG − Asp-62→Tyr TGAGGTGGTGCCGGATGTCATATTCAGCAG 3′ LV27 5′GATTGGATCCAACACATCATTCGAGCTG 3′ + Δ Ndel LV182 5′GGATTGAAAATGCAATTAATTCATGTAT 3′ − Δ Ndel 118U250 (14755) 5′CAGCCAGGGGAAAATGTGGC 3′ − Sequencing LV37 (14340) 5′GATTGGATCCACCATGGAGTCATGGAAGTTTATCACT 3′ + Sequencing LV75 (15088) 5′TCTAGGAATTCTAGACGATCG 3′ − Sequencing LV76 (15088) 5′TCTAGGAATTCTAGACGATCG(T)403′ − RT-PCR LV82 (14703) 5′AGCAACCTAGGGGAGGACAG 3′ + Sequencing LV108 (14566) 5′GGAGTGGTTAACCTCGTCAAGTATGGCCGGTAAAAACCAGAGCC 3′ + ORF7-HA LV112 (14958) 5′CCATTCACCTGACTGTTTAATTAACTTGCACCCTGA 3′ − Pacl site LV139 (14609) 5′AACTTTGACCTTCTCAAGTTGGCCGGCGACGTCGAGTCCAA + 1st HA-prot-ORF7 CCCAGGGCCCGGTAAAAACCAGAGCCAGAA 3′ LV140 (14609) 5′GAGTGGTTAACCTCGTCAAGTATGGCCGGTAAATACCCATACGAT + 2nd HA-prot-ORF7 GTTCCAGATTACGCT0AACTTTGACCTTCT 3′ LV188 (14687) 5′ACGTGCGTTAACTAAGGTGCAATGATAAAGTCCCA 3′ + Δ 99 nt. 5′ORF7 LV189 (14796) 5′ACGTGCGTTAACTAAATCCGGCACCACCTCACCCA 3′ + Δ 198 nt. 5′ORF7 LV190 (14885) 5′ACGTGCGTTAACTAAGGGAAGGTCAGTTTTCAGGT 3′ + Δ 297 nt. 5′ORF7 LV191 (14936) 5′ACGTGCGTTAACTAACGCCTGATTCGCGTGACTTC 3′ + Δ 348 nt. 5′ORF7 LV192 (14609) 5′AAATACCCATACGATGTTCCAGATTACGCTAACCAGAGCCA 3′ + 1st HA-ORF7 LV193 (14609) 5′AGTGGTTAACCTCGTCAAGTATGGCCGGTAAA TACCCATACG 3′ = 2nd HA-ORF7 LV194 (14971) 5′ACTGTTTAATTAAGCGTAATCTGGAACATCGTA − ORF7-HA TGGGTAACTTGCACCCTG 3′ LV195 (14642) 5′ACGTGCGTTAACTAACCGATGGGGAATGGCCAG 3′ + Δ 55 nt 5′ORF7 LV196 (14642) 5′GGAGTGGTTAACCTCGTCAAGTAACCGATGGGGAATGGCCAG 3′ + Δ 45 nt 5′ORF7 LV197 (14597) 5′ACGTGCGTTAACGGCCGGTAAAAACCAGAGC 3′ + Δ 10 nt 3′ORF6 LV198 (141333) 5′GCTCGTGCTAGCCTTTAGCATCACATACAC 3′ + Δ 54 nt 3′ORF6 LV199 (14596) 5′CTTGACGAGGTTAACTGGTACTAGAGTGCC 3′ − Δ 54 nt 3′ORF6 -
TABLE 2 Staining of LV4.2.1, vABV600 (Asp-62→Tyr mutation), ATCCVR2332-like PRRSV containing an Asp61→ Tyr mutation in the N protein, and ATCC-VR2332 with various N-specific MAbs in IPMA vABV600 ATCCVR2332- (Asp-62→ like (Asp61→ MAb Site LV4.2.1 Tyr) Tyr) ATCC-VR2332 138.22 A + + − − NS99 B + + + + 122.17 D ++ ++ ++ ++ 130.2 D ++ −1) − + 130.4 D ++ −1) − + 131.7 D ++ −1) − + 131.9 D ++ −1) − + SDOW17 D ++ −1) −1) ++ WBE1 D + − − − WBE4 D ++ ++ − − WBE5 D ++ ++ − − WBE6 D ++ ++ − − VO17 ? − − + + -
-
1 29 1 6 PRT Porcine reproductive and respiratory syndrome virus 1 Gln Leu Cys Gln Leu Leu 1 5 2 17 PRT Porcine reproductive and respiratory virus 2 Pro Glu Lys Pro His Phe Pro Leu Ala Ala Glu Asp Asp Ile Arg His 1 5 10 15 His 3 11 PRT Porcine reproductive and respiratory virus 3 Ile Ser Thr Ala Phe Asn Gln Gly Ala Gly Thr 1 5 10 4 26 DNA Artificial Sequence PCR Primer 4 cattgcaccc agaactggtt cagttg 26 5 27 DNA Artificial Sequence PCR Primer 5 cgtctggatc gattgcaaga ggaggga 27 6 69 DNA Artificial Sequence PCR Primer 6 tctggatcga ttgcaagcag agggagcgtt cagtctgggt gaggtggtgc cggatgtcat 60 attcagcag 69 7 28 DNA Artificial Sequence PCR Primer 7 gattggatcc aacacatcat tcgagctg 28 8 28 DNA Artificial Sequence PCR Primer 8 ggattgaaaa tgcaattaat tcatgtat 28 9 20 DNA Artificial Sequence PCR Primer 9 cagccagggg aaaatgtggc 20 10 37 DNA Artificial Sequence PCR Primer 10 gattggatcc accatggagt catggaagtt tatcact 37 11 21 DNA Artificial Sequence PCR Primer 11 tctaggaatt ctagacgatc g 21 12 22 DNA Artificial Sequence PCR Primer 12 tctaggaatt ctagacgatc gt 22 13 20 DNA Artificial Sequence PCR Primer 13 agcaacctag gggaggacag 20 14 44 DNA Artificial Sequence PCR Primer 14 ggagtggtta acctcgtcaa gtatggccgg taaaaaccag agcc 44 15 36 DNA Artificial Sequence PCR Primer 15 ccattcacct gactgtttaa ttaacttgca ccctga 36 16 72 DNA Artificial Sequence PCR Primer 16 aactttgacc ttctcaagtt ggccggcgac gtcgagtcca acccagggcc cggtaaaaac 60 cagagccaga ag 72 17 75 DNA Artificial Sequence PCR Primer 17 gagtggttaa cctcgtcaag tatggccggt aaatacccat acgatgttcc agattacgct 60 aactttgacc ttctc 75 18 35 DNA Artificial Sequence PCR Primer 18 acgtgcgtta actaaggtgc aatgataaag tccca 35 19 35 DNA Artificial Sequence PCR Primer 19 acgtgcgtta actaaatccg gcaccacctc accca 35 20 35 DNA Artificial Sequence PCR Primer 20 acgtgcgtta actaagggaa ggtcagtttt caggt 35 21 35 DNA Artificial Sequence PCR Primer 21 acgtgcgtta actaacgcct gattcgcgtg acttc 35 22 41 DNA Artificial Sequence PCR Primer 22 aaatacccat acgatgttcc agattacgct aaccagagcc a 41 23 42 DNA Artificial Sequence PCR Primer 23 agtggttaac ctcgtcaagt atggccggta aatacccata cg 42 24 51 DNA Artificial Sequence PCR Primer 24 actgtttaat taagcgtaat ctggaacatc gtatgggtaa cttgcaccct g 51 25 33 DNA Artificial Sequence PCR Primer 25 acgtgcgtta actaaccgat ggggaatggc cag 33 26 42 DNA Artificial Sequence PCR Primer 26 ggagtggtta acctcgtcaa gtaaccgatg gggaatggcc ag 42 27 31 DNA Artificial Sequence PCR Primer 27 acgtgcgtta acggccggta aaaaccagag c 31 28 30 DNA Artificial Sequence PCR Primer 28 gctcgtgcta gcctttagca tcacatacac 30 29 30 DNA Artificial Sequence PCR Primer 29 cttgacgagg ttaactggta ctagagtgcc 30
Claims (21)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/422,970 US8790656B2 (en) | 1996-10-30 | 2006-06-08 | PRRSV vaccines |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99200668.4 | 1999-03-08 | ||
EP99200668 | 1999-03-08 | ||
PCT/NL2000/000152 WO2000053787A1 (en) | 1999-03-08 | 2000-03-08 | Prrsv vaccines |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL2000/000152 Continuation WO2000053787A1 (en) | 1996-10-30 | 2000-03-08 | Prrsv vaccines |
US09/874,626 Continuation-In-Part US20020098573A1 (en) | 1996-10-30 | 2001-06-05 | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/422,970 Continuation US8790656B2 (en) | 1996-10-30 | 2006-06-08 | PRRSV vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030049274A1 true US20030049274A1 (en) | 2003-03-13 |
Family
ID=8239954
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/948,747 Abandoned US20030049274A1 (en) | 1996-10-30 | 2001-09-07 | PRRSV vaccines |
US11/422,970 Expired - Fee Related US8790656B2 (en) | 1996-10-30 | 2006-06-08 | PRRSV vaccines |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/422,970 Expired - Fee Related US8790656B2 (en) | 1996-10-30 | 2006-06-08 | PRRSV vaccines |
Country Status (7)
Country | Link |
---|---|
US (2) | US20030049274A1 (en) |
EP (1) | EP1157121B1 (en) |
JP (1) | JP3961222B2 (en) |
AU (1) | AU3198200A (en) |
CA (1) | CA2366072C (en) |
PL (1) | PL204373B1 (en) |
WO (1) | WO2000053787A1 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040197872A1 (en) * | 1996-10-30 | 2004-10-07 | Meulenberg Johanna Jacoba Maria | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
US20040224327A1 (en) * | 1996-10-30 | 2004-11-11 | Meulenberg Johanna Jacoba Maria | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
US20050137705A1 (en) * | 1999-10-22 | 2005-06-23 | Reiley Mark A. | Facet arthroplasty devices and methods |
US20060240041A1 (en) * | 1996-10-30 | 2006-10-26 | Meulenberg Johanna J M | PRRSV Vaccines |
US20070042000A1 (en) * | 1999-04-22 | 2007-02-22 | Mengeling William L | Porcine reproductive and respiratory syndrome vaccine based on isolate ja-142 |
US20080311143A1 (en) * | 2007-06-15 | 2008-12-18 | Protatek International, Inc. | Construction of chimera prrsv, compositions and vaccine preparations |
US20090130143A1 (en) * | 2005-02-25 | 2009-05-21 | Dongwan Yoo | N protein mutants of porcine reproductive and respiratory syndrome virus |
US20100035276A1 (en) * | 2004-06-18 | 2010-02-11 | Regents of of the University of Minnesota | Identifying virally infected and vaccinated organisms |
US20110059126A1 (en) * | 2009-09-02 | 2011-03-10 | Boehringer Ingelheim Vetmedica, Inc. | Methods of reducing virucidal activity in pcv-2 compositions and pcv-2 compositions with an improved immunogenicity |
US20110117129A1 (en) * | 2008-08-25 | 2011-05-19 | Boehringer Ingelheim Vetmedica, Inc. | Vaccine Against Highly Pathogenic Porcine Reproductive and Respiratory Syndrome (HP PRRS) |
US20110195088A1 (en) * | 2004-09-21 | 2011-08-11 | Boehringer Ingelheim Vetmedica, Inc. | Porcine Reproductive and Respiratory Syndrome Isolates and Methods of Use |
US8765142B2 (en) | 2011-02-17 | 2014-07-01 | Boehringer Ingelheim Vetmedica Gmbh | European PRRSV strain |
US9080143B2 (en) | 2005-06-24 | 2015-07-14 | University Of Minnesota | PRRS viruses, infectious clones, mutants thereof, and method of use |
US9187731B2 (en) | 2011-07-29 | 2015-11-17 | Boehringer Ingelheim Vetmedica Gmbh | PRRS virus inducing type I interferon in susceptible cells |
US9315781B2 (en) | 2011-07-29 | 2016-04-19 | Boehringer Ingelheim Vetmedica Gmbh | Infectious CDNA clone of european PRRS virus and uses thereof |
US9579373B2 (en) | 2013-03-15 | 2017-02-28 | Boehringer Ingelheim Vetmedica, Inc. | Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use |
US9944902B2 (en) | 2011-02-17 | 2018-04-17 | Boehringer Ingelheim Vetmedica Gmbh | Commercial scale process for production of PRRSV |
US10010601B2 (en) | 2013-12-20 | 2018-07-03 | Boehringer Ingelheim Vetmedica Gmbh | PRRS virus variant, European PRRS virus cDNA clone, and uses thereof |
CN114395583A (en) * | 2021-11-01 | 2022-04-26 | 扬州大学 | cDNA clone of porcine reproductive and respiratory syndrome virus expressing secreted luciferase and construction method and application thereof |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1156111A1 (en) | 2000-05-19 | 2001-11-21 | Stichting Dienst Landbouwkundig Onderzoek | Chimeric arterivirus-like particles |
SK11282003A3 (en) * | 2001-03-09 | 2004-02-03 | Boehringer Ingelheim Vetmedica Gmbh | Life attenuated European PRRS virus, nucleotide sequence coding said virus, method of generating such virus, cell line, and a pharmaceutical composition comprising said PRRS viruses and the use thereof |
EP1397498A1 (en) * | 2001-05-21 | 2004-03-17 | ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid B.V. | Delections in arterivirus replicons |
US7595054B2 (en) * | 2003-06-09 | 2009-09-29 | Healthbanks Biotech Co., Ltd. | Fusion antigen used as vaccine |
US8206950B2 (en) * | 2003-06-09 | 2012-06-26 | Animal Technology Institute Taiwan | Fusion antigen used as vaccine and method of making them |
WO2006093797A2 (en) | 2005-02-28 | 2006-09-08 | Mj Biologics, Inc. | Method and kit for detecting porcine reproductive and respiratory syndrome virus |
DE602006013003D1 (en) * | 2005-08-30 | 2010-04-29 | Univ Nebraska | METHOD AND COMPOSITIONS FOR VACCINATING ANIMALS WITH PRRSV ANTIGENES WITH IMPROVED IMMUNOGENICITY |
CA2691755A1 (en) * | 2007-06-25 | 2008-12-31 | South Dakota State University | Recombinant north american type 1 porcine reproductive and respiratory syndrome virus and methods of use |
US20090246226A1 (en) * | 2008-03-28 | 2009-10-01 | Zeon Corporation | Avian vaccines possessing a positive marker gene |
CN101748125B (en) * | 2008-12-11 | 2012-05-30 | 中国科学院动物研究所 | siRNA segment and application thereof used for curing and/or preventing Porcine Reproductive and Respiratory Syndrome |
US9132185B2 (en) | 2010-06-02 | 2015-09-15 | Virginia Tech Intellectual Properties, Inc. | Modified live-attenuated vaccines (MLV) created by DNA shuffling against porcine reproductive and respiratory syndrome virus (PRRSV) |
ES2674439T3 (en) * | 2011-06-01 | 2018-06-29 | Merial, Inc. | Needle-free administration of VSRRP vaccines |
CN103087996B (en) * | 2013-01-18 | 2014-07-16 | 中国农业大学 | Recombinant porcine reproductive and respiratory syndrome virus as well as preparation method and application thereof |
CN104991061B (en) * | 2015-06-12 | 2017-04-12 | 中国农业科学院哈尔滨兽医研究所 | Peste des petits ruminant virus antibody detection kit based on IPMA |
US10279031B2 (en) | 2016-05-11 | 2019-05-07 | Phibro Animal Health Corporation | Composition comprising antigens and a mucosal adjuvant and a method for using |
CN111748530B (en) * | 2020-07-20 | 2023-08-15 | 河南省农业科学院 | Method for improving in-vitro culture infection amount of porcine reproductive and respiratory syndrome virus and application thereof |
Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3137631A (en) * | 1959-12-01 | 1964-06-16 | Faberge Inc | Encapsulation in natural products |
US3959457A (en) * | 1970-06-05 | 1976-05-25 | Temple University | Microparticulate material and method of making such material |
US4015100A (en) * | 1974-01-07 | 1977-03-29 | Avco Everett Research Laboratory, Inc. | Surface modification |
US4205060A (en) * | 1978-12-20 | 1980-05-27 | Pennwalt Corporation | Microcapsules containing medicament-polymer salt having a water-insoluble polymer sheath, their production and their use |
US4452747A (en) * | 1982-03-22 | 1984-06-05 | Klaus Gersonde | Method of and arrangement for producing lipid vesicles |
US4606940A (en) * | 1984-12-21 | 1986-08-19 | The Ohio State University Research Foundation | Small particle formation and encapsulation |
US4744933A (en) * | 1984-02-15 | 1988-05-17 | Massachusetts Institute Of Technology | Process for encapsulation and encapsulated active material system |
US4921706A (en) * | 1984-11-20 | 1990-05-01 | Massachusetts Institute Of Technology | Unilamellar lipid vesicles and method for their formation |
US4927637A (en) * | 1989-01-17 | 1990-05-22 | Liposome Technology, Inc. | Liposome extrusion method |
US4944948A (en) * | 1989-02-24 | 1990-07-31 | Liposome Technology, Inc. | EGF/Liposome gel composition and method |
US5008050A (en) * | 1984-06-20 | 1991-04-16 | The Liposome Company, Inc. | Extrusion technique for producing unilamellar vesicles |
US5009956A (en) * | 1987-02-24 | 1991-04-23 | Univ Minnesota | Phospholipase A2-resistant liposomes |
US5132117A (en) * | 1990-01-11 | 1992-07-21 | Temple University | Aqueous core microcapsules and method for their preparation |
US5476778A (en) * | 1991-08-26 | 1995-12-19 | Boehringer Ingelheim Animal Health, Inc. | Method of growing and attenuating a viral agent associated with mystery swine disease |
US5510258A (en) * | 1993-02-08 | 1996-04-23 | Bayer Corporation | Porcine reproductive and respiratory syndrome virus antigen and processes for the preparation and use of said antigen in vaccines and diagnostics |
US5620691A (en) * | 1991-06-06 | 1997-04-15 | Stichting Centraal Diergeneeskundig Instituut | Causative agent of the mystery swine disease, vaccine compositions and diagnostic kits |
US5677429A (en) * | 1991-08-26 | 1997-10-14 | South Dakota State University | Monoclonal antibodies to the Mystery Swine Disease virus |
US5690940A (en) * | 1995-06-21 | 1997-11-25 | Regents Of The University Of Minnesota | Low pathogencity PRRS live virus vaccines and methods of preparation thereof |
US5695766A (en) * | 1992-10-30 | 1997-12-09 | Iowa State University Research Foundation | Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome |
US5840563A (en) * | 1991-08-26 | 1998-11-24 | Boehringer Ingelheim Animal Health, Inc. | Method for growing swine infertility and respiratory syndrome virus |
US5998601A (en) * | 1994-08-05 | 1999-12-07 | Regents Of The University Of Minnesota | VR-2332 viral nucleotide sequence and methods of use |
US6251397B1 (en) * | 1992-10-30 | 2001-06-26 | Iowa State University Research Foundation, Inc. | Proteins encoded by polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus and immunogenic compositions containing the same |
US6495138B1 (en) * | 1997-05-06 | 2002-12-17 | Stichting Dienst Landbouwkundig Onderzoek | PRRSV antigenic sites identifying peptide sequences of PRRS virus for use in vaccines or diagnostic assays |
US6500662B1 (en) * | 1998-12-22 | 2002-12-31 | Pfizer Inc. | Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof |
US20030157689A1 (en) * | 1998-12-22 | 2003-08-21 | Calvert Jay G. | Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3080291A (en) * | 1960-06-10 | 1963-03-05 | Jensen Salsberg Lab Inc | Serial passage of distemper virus in tissue cultures of chick embryo and canine tissue and vaccine therefrom |
US4122167A (en) * | 1977-02-09 | 1978-10-24 | Merck & Co., Inc. | Respiratory synctial vaccine |
US4224412A (en) * | 1979-05-01 | 1980-09-23 | Dorofeev Viktor M | Living virus culture vaccine against canine distemper and method of preparing same |
US4554159A (en) * | 1981-11-12 | 1985-11-19 | Institute Merieux | Vaccine and method of immunizing against herpes simplex virus (types 1 and 2) |
US4468346A (en) * | 1983-10-27 | 1984-08-28 | The United States Of America As Represented By The Secretary Of Agriculture | Monoclonal antibodies to porcine immunoglobulins |
DE3405100A1 (en) * | 1984-02-14 | 1985-08-14 | Drägerwerk AG, 2400 Lübeck | PT CATALYST ON A CARRIER AS AN AIR PURIFIER |
US5206163A (en) * | 1985-07-08 | 1993-04-27 | Chiron Corporation | DNA encoding bovine diarrhea virus protein |
US4753884A (en) * | 1986-01-28 | 1988-06-28 | Novagene, Inc. | Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same |
FR2602791B1 (en) * | 1986-08-18 | 1988-11-10 | Ministere Agri Direction Quali | METHOD FOR CULTURING TURKEY INFECTIOUS RHINOTRACHEITIS VIRUS, AND VACCINE PREPARED FROM THE VIRUS OBTAINED THEREBY |
NZ222465A (en) | 1986-11-07 | 1992-11-25 | Pasteur Institut | Nanb (non a, non b hepatitis viral) antigen |
DE3833925A1 (en) | 1988-03-11 | 1989-09-21 | Inst Angewandte Biotechnologie | PROCESS AND MANUFACTURE OF VIRUS AND VIRAL ANTIGEN AND DEVICE THEREFOR |
US5213759A (en) * | 1988-05-05 | 1993-05-25 | Elopak Systems A.G. | Sterilization |
AU7007491A (en) | 1990-02-02 | 1991-08-08 | Schweiz. Serum- & Impfinstitut Bern | Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses |
US6042830A (en) | 1992-08-05 | 2000-03-28 | Boehringer Ingelheim Vetmedica, Inc. | Viral agent associated with mystery swine disease |
US6080570A (en) * | 1991-08-26 | 2000-06-27 | Boehringer Ingelheim Vetmedica, Inc. | Method of producing a vaccine for Swine Infertility and Respiratory Syndrome |
US6982160B2 (en) * | 1991-08-26 | 2006-01-03 | Boehringer Ingelheim Vetmedica, Inc. | Immunogenic compositions that include SIRS virus |
WO1993006211A1 (en) | 1991-09-16 | 1993-04-01 | Collins James E | Vaccine for mystery swine disease and method for diagnosis thereof |
AU2684792A (en) | 1991-10-14 | 1993-05-21 | Akzo Nobel N.V. | Porcine reproductive respiratory syndrome vaccine and diagnostic |
FR2686097B1 (en) * | 1992-01-14 | 1994-12-30 | Rhone Merieux | PREPARATION OF ANTIGENS AND MYSTERY DISEASE VIRUS VACCINES, ANTIGENS AND VACCINES OBTAINED FOR THE PREVENTION OF THIS DISEASE. |
US5338543A (en) * | 1992-02-27 | 1994-08-16 | Ambico, Inc. | Thimerosal inactivated mycoplasma hyopneumoniae vaccine |
TW289731B (en) * | 1992-07-09 | 1996-11-01 | Akzo Nv | |
US6592873B1 (en) * | 1992-10-30 | 2003-07-15 | Iowa State University Research Foundation, Inc. | Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids |
US6773908B1 (en) * | 1992-10-30 | 2004-08-10 | Iowa State University Research Foundation, Inc. | Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV) |
US6380376B1 (en) * | 1992-10-30 | 2002-04-30 | Iowa State University Research Foundation | Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV) |
US5419907A (en) * | 1992-11-10 | 1995-05-30 | Iowa State University Research Foundation, Inc. | Pathogenic porcine respiratory coronavirus |
ES2074950B1 (en) | 1993-09-17 | 1996-03-16 | Iberica Cyanamid | VACCINE FOR THE PREVENTION OF REPRODUCTIVE AND RESPIRATORY DISEASE OF THE SOW. |
EP0659885A1 (en) * | 1993-12-21 | 1995-06-28 | Akzo Nobel N.V. | Vaccine against viruses associated with antibody-dependent-enhancement of viral infectivity |
DE4407489A1 (en) * | 1994-03-07 | 1995-09-14 | Bayer Ag | Vaccine for the prevention of respiratory and reproductive diseases of the pig |
DE69522984T2 (en) * | 1994-04-11 | 2002-04-25 | Akzo Nobel Nv | Pig reproductive respiratory syndrome virus vaccine European strains |
DE69530227T2 (en) | 1994-04-15 | 2004-04-01 | Temple University | CAPSULE METHOD WITH AQUEOUS SOLVENT AND MICROCAPSULES |
DK53595A (en) | 1994-05-13 | 1995-11-14 | Iberica Cyanamid | Recombinant PRRSV proteins, diagnostic kits and vaccines containing such recombinant PRRSV proteins |
DE69632658T2 (en) * | 1995-03-14 | 2005-06-09 | Akzo Nobel N.V. | Expression in the same cell of porcine reproductive and respiratory syndrome polypeptides |
ES2102971B1 (en) | 1996-01-25 | 1998-03-01 | Hipra Lab Sa | NEW ATTENUATED STRAIN OF THE VIRUS CAUSING THE RESPIRATORY AND REPRODUCTIVE SYNDROME (PRRS), THE VACCINES AND DIAGNOSTIC MEDIA OBTAINABLE WITH THE SAME AND THE PROCEDURES FOR ITS OBTAINING. |
CO4600644A1 (en) | 1996-03-01 | 1998-05-08 | Schering Corp | VACCINE AGAINST SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME |
US5866401A (en) * | 1996-03-01 | 1999-02-02 | Schering Corporation | Porcine reproductive and respiratory syndrome vaccine |
US6015663A (en) * | 1996-03-01 | 2000-01-18 | The United States Of America As Represented By The Secretary Of Agriculture | Restriction enzyme screen for differentiating porcine reproductive and respiratory syndrome virus strains |
US5976537A (en) * | 1996-07-02 | 1999-11-02 | The United States Of America As Represented By The Secretary Of Agriculture | Porcine reproductive and respiratory syndrome vaccine |
DE69704011T2 (en) * | 1996-10-09 | 2001-06-07 | Akzo Nobel Nv | Swine Reproductive System Respiratory Syndrome Virus (PRRSV) vaccine strains |
EP0839912A1 (en) | 1996-10-30 | 1998-05-06 | Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
US20040224327A1 (en) * | 1996-10-30 | 2004-11-11 | Meulenberg Johanna Jacoba Maria | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
WO1998035023A1 (en) | 1997-02-07 | 1998-08-13 | Origen, Inc. | Method for growing porcine reproductive and respiratory syndrome virus for use as vaccines and diagnostic assays |
WO1998055626A2 (en) * | 1997-06-05 | 1998-12-10 | Origen, Inc. | Recombinant porcine reproductive and respiratory syndrome virus (prrsv) for use as a vaccine |
US7211379B2 (en) * | 1997-10-03 | 2007-05-01 | Merial Sas | Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2 |
US6391314B1 (en) * | 1997-10-03 | 2002-05-21 | Merial | Porcine circoviruses vaccines diagnostic reagents |
US7618797B2 (en) | 1998-12-22 | 2009-11-17 | Pfizer Inc | Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof |
US7691389B2 (en) | 1998-12-22 | 2010-04-06 | Pfizer Inc | Infectious cDNA clone of north american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof |
FR2789695B1 (en) * | 1999-02-11 | 2003-03-07 | Merial Sas | VIRAL VACCINES AND VACCINES BASED ON RECOMBINANT AND REPLICATIVE SWINE ADENOVIRUSES |
AU3198200A (en) * | 1999-03-08 | 2000-09-28 | Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. | Prrsv vaccines |
ATE474041T1 (en) | 1999-04-22 | 2010-07-15 | Us Agriculture | VACCINE BASED ON ISOLATE JA-142 AGAINST REPRODUCTIVE AND RESPIRATORY SYNDROME IN SWINE |
US20040213805A1 (en) * | 1999-10-12 | 2004-10-28 | Verheije Monique Helene | Deletions in arterivirus replicons |
US20020012670A1 (en) * | 2000-01-26 | 2002-01-31 | Knut Elbers | Recombinant attenuation of porcine reproductive and respiratory syndrome (PRRSV) |
US7041443B2 (en) | 2000-02-08 | 2006-05-09 | Regents Of The University Of Minnesota | Porcine reproductive and respiratory syndrome virus and methods of use |
EP1156111A1 (en) * | 2000-05-19 | 2001-11-21 | Stichting Dienst Landbouwkundig Onderzoek | Chimeric arterivirus-like particles |
US7018638B2 (en) * | 2000-12-19 | 2006-03-28 | Wyeth | Mycoplasma hyopneumoniae bacterin vaccine |
EP1397498A1 (en) | 2001-05-21 | 2004-03-17 | ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid B.V. | Delections in arterivirus replicons |
US7279166B2 (en) * | 2001-12-12 | 2007-10-09 | Virginia Tech Intellectual Properties, Inc. | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof |
US6841364B2 (en) * | 2002-01-22 | 2005-01-11 | Protatek International, Inc. | Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof |
EP1350840B1 (en) * | 2002-04-05 | 2012-05-09 | Boehringer Ingelheim Vetmedica GmbH | Adaptation sites of PRRSV |
US7335361B2 (en) | 2003-06-09 | 2008-02-26 | Animal Technology Institute Taiwan | Fusion antigen used as vaccine |
US7722878B2 (en) | 2004-06-17 | 2010-05-25 | Boehringer Ingelheim Vetmedica, Inc. | PRRSV subunit vaccines |
KR20070028547A (en) | 2004-06-18 | 2007-03-12 | 리전츠 오브 더 유니버스티 오브 미네소타 | Identifying virally infected and vaccinated organisms |
US7632636B2 (en) | 2004-09-21 | 2009-12-15 | Boehringer Ingelheim Vetmedica, Inc. | Porcine reproductive and respiratory syndrome isolates and methods of use |
US20060063151A1 (en) * | 2004-09-21 | 2006-03-23 | Michael Roof | Porcine reproductive and respiratory syndrome isolates and methods of use |
KR20070096019A (en) | 2005-01-13 | 2007-10-01 | 베링거잉겔하임베트메디카게엠베하 | Improved prrs vaccines |
CN101495138B (en) | 2005-11-29 | 2014-01-08 | 衣阿华州立大学研究基金公司 | Identification of protective antigenic determinants of porcine reproductive and respiratory syndrome virus (prrsv) and uses thereof |
US8563313B2 (en) | 2007-02-13 | 2013-10-22 | Washington State University Research Foundation | Macrophage cell-lines for propagation of porcine reproductive and respiratory syndrome virus |
WO2008121958A1 (en) | 2007-04-02 | 2008-10-09 | Boehringer Ingelheim Vetmedica, Inc. | Use of prrsv vaccines to reduce pcv2 viremia |
US20100003278A1 (en) | 2008-07-03 | 2010-01-07 | Boehringer Ingelheim Vetmedica, Inc. | Immunological Compositions Effective for Lessening the Severity or Incidence of PRRSV Signs and Methods of Use Thereof |
RU2561595C2 (en) | 2008-08-25 | 2015-08-27 | Бёрингер Ингельхайм Ветмедика, Инк. | Vaccine against highly pathogenic porcine reproductive and respiratory syndrome (hp prrs) |
US20100129398A1 (en) | 2008-11-26 | 2010-05-27 | Boehringer Ingelheim Vetmedica, Inc. | Materials and Methods for Control of Porcine Reproductive and Respiratory Syndrome |
WO2011128415A1 (en) | 2010-04-16 | 2011-10-20 | Universiteit Gent | Cross-protecting vaccine for porcine reproductive and respiratory syndrome virus |
US8728487B2 (en) | 2011-01-20 | 2014-05-20 | Hua Wu | Attenuated live vaccine for prevention of porcine reproductive and respiratory syndrome |
-
2000
- 2000-03-08 AU AU31982/00A patent/AU3198200A/en not_active Abandoned
- 2000-03-08 JP JP2000603408A patent/JP3961222B2/en not_active Expired - Fee Related
- 2000-03-08 PL PL351486A patent/PL204373B1/en not_active IP Right Cessation
- 2000-03-08 CA CA002366072A patent/CA2366072C/en not_active Expired - Fee Related
- 2000-03-08 EP EP00909797.3A patent/EP1157121B1/en not_active Expired - Lifetime
- 2000-03-08 WO PCT/NL2000/000152 patent/WO2000053787A1/en active Search and Examination
-
2001
- 2001-09-07 US US09/948,747 patent/US20030049274A1/en not_active Abandoned
-
2006
- 2006-06-08 US US11/422,970 patent/US8790656B2/en not_active Expired - Fee Related
Patent Citations (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3137631A (en) * | 1959-12-01 | 1964-06-16 | Faberge Inc | Encapsulation in natural products |
US3959457A (en) * | 1970-06-05 | 1976-05-25 | Temple University | Microparticulate material and method of making such material |
US4015100A (en) * | 1974-01-07 | 1977-03-29 | Avco Everett Research Laboratory, Inc. | Surface modification |
US4205060A (en) * | 1978-12-20 | 1980-05-27 | Pennwalt Corporation | Microcapsules containing medicament-polymer salt having a water-insoluble polymer sheath, their production and their use |
US4452747A (en) * | 1982-03-22 | 1984-06-05 | Klaus Gersonde | Method of and arrangement for producing lipid vesicles |
US4744933A (en) * | 1984-02-15 | 1988-05-17 | Massachusetts Institute Of Technology | Process for encapsulation and encapsulated active material system |
US5008050A (en) * | 1984-06-20 | 1991-04-16 | The Liposome Company, Inc. | Extrusion technique for producing unilamellar vesicles |
US4921706A (en) * | 1984-11-20 | 1990-05-01 | Massachusetts Institute Of Technology | Unilamellar lipid vesicles and method for their formation |
US4606940A (en) * | 1984-12-21 | 1986-08-19 | The Ohio State University Research Foundation | Small particle formation and encapsulation |
US5009956A (en) * | 1987-02-24 | 1991-04-23 | Univ Minnesota | Phospholipase A2-resistant liposomes |
US4927637A (en) * | 1989-01-17 | 1990-05-22 | Liposome Technology, Inc. | Liposome extrusion method |
US4944948A (en) * | 1989-02-24 | 1990-07-31 | Liposome Technology, Inc. | EGF/Liposome gel composition and method |
US5132117A (en) * | 1990-01-11 | 1992-07-21 | Temple University | Aqueous core microcapsules and method for their preparation |
US6455245B1 (en) * | 1991-06-06 | 2002-09-24 | Stichting Centraal Diergeneeskundig Instituut | Mystery swine disease diagnostic kits |
US6197310B1 (en) * | 1991-06-06 | 2001-03-06 | Stichting Centraal Diergeneeskundig Instituut | Causative agent of the mystery swine disease, vaccine compositions and diagnostics kits |
US5620691A (en) * | 1991-06-06 | 1997-04-15 | Stichting Centraal Diergeneeskundig Instituut | Causative agent of the mystery swine disease, vaccine compositions and diagnostic kits |
US5846805A (en) * | 1991-08-26 | 1998-12-08 | Boehringer Ingelheim Animal Health, Inc. | Culture of swine infertility and respiratory syndrome virus in simian cells |
US5476778A (en) * | 1991-08-26 | 1995-12-19 | Boehringer Ingelheim Animal Health, Inc. | Method of growing and attenuating a viral agent associated with mystery swine disease |
US5683865A (en) * | 1991-08-26 | 1997-11-04 | South Dakota State University | Method for diagnosis of mystery swine disease |
US5677429A (en) * | 1991-08-26 | 1997-10-14 | South Dakota State University | Monoclonal antibodies to the Mystery Swine Disease virus |
US5840563A (en) * | 1991-08-26 | 1998-11-24 | Boehringer Ingelheim Animal Health, Inc. | Method for growing swine infertility and respiratory syndrome virus |
US5695766A (en) * | 1992-10-30 | 1997-12-09 | Iowa State University Research Foundation | Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome |
US6110467A (en) * | 1992-10-30 | 2000-08-29 | Iowa State University Research Foundation | Isolated porcine respiratory and reproductive virus, vaccines and methods of protecting a pig against a disease caused by a porcine respiratory and reproductive virus |
US6251397B1 (en) * | 1992-10-30 | 2001-06-26 | Iowa State University Research Foundation, Inc. | Proteins encoded by polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus and immunogenic compositions containing the same |
US5510258A (en) * | 1993-02-08 | 1996-04-23 | Bayer Corporation | Porcine reproductive and respiratory syndrome virus antigen and processes for the preparation and use of said antigen in vaccines and diagnostics |
US5998601A (en) * | 1994-08-05 | 1999-12-07 | Regents Of The University Of Minnesota | VR-2332 viral nucleotide sequence and methods of use |
US5690940A (en) * | 1995-06-21 | 1997-11-25 | Regents Of The University Of Minnesota | Low pathogencity PRRS live virus vaccines and methods of preparation thereof |
US6495138B1 (en) * | 1997-05-06 | 2002-12-17 | Stichting Dienst Landbouwkundig Onderzoek | PRRSV antigenic sites identifying peptide sequences of PRRS virus for use in vaccines or diagnostic assays |
US6500662B1 (en) * | 1998-12-22 | 2002-12-31 | Pfizer Inc. | Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof |
US20030157689A1 (en) * | 1998-12-22 | 2003-08-21 | Calvert Jay G. | Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8790656B2 (en) | 1996-10-30 | 2014-07-29 | Boehringer Ingelheim Vetmedica Gmbh | PRRSV vaccines |
US20040224327A1 (en) * | 1996-10-30 | 2004-11-11 | Meulenberg Johanna Jacoba Maria | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
US8546124B2 (en) | 1996-10-30 | 2013-10-01 | Boehringer Ingelheim Vetmedica Gmbh | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
US20060205033A1 (en) * | 1996-10-30 | 2006-09-14 | Boehringer Ingelheim Vetmedica Gmbh | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
US20060240041A1 (en) * | 1996-10-30 | 2006-10-26 | Meulenberg Johanna J M | PRRSV Vaccines |
US20040197872A1 (en) * | 1996-10-30 | 2004-10-07 | Meulenberg Johanna Jacoba Maria | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
US8741309B2 (en) | 1999-04-22 | 2014-06-03 | The United States Of America As Represented By The Secretary Of Agriculture | Porcine reproductive and respiratory syndrome vaccine based on isolate JA-142 |
US8747859B2 (en) | 1999-04-22 | 2014-06-10 | The United States Of America, As Represented By The Secretary Of Agriculture | Porcine reproductive and respiratory syndrome vaccine based on isolate JA-142 |
US20070042000A1 (en) * | 1999-04-22 | 2007-02-22 | Mengeling William L | Porcine reproductive and respiratory syndrome vaccine based on isolate ja-142 |
US20110104201A1 (en) * | 1999-04-22 | 2011-05-05 | Mengeling William L | Porcine Reproductive and Respiratory Syndrome Vaccine Based on Isolate JA-142 |
US20050137705A1 (en) * | 1999-10-22 | 2005-06-23 | Reiley Mark A. | Facet arthroplasty devices and methods |
US20100035276A1 (en) * | 2004-06-18 | 2010-02-11 | Regents of of the University of Minnesota | Identifying virally infected and vaccinated organisms |
US8399187B2 (en) | 2004-06-18 | 2013-03-19 | Regents Of The University Of Minnesota | Identifying virally infected and vaccinated organisms |
US20110195088A1 (en) * | 2004-09-21 | 2011-08-11 | Boehringer Ingelheim Vetmedica, Inc. | Porcine Reproductive and Respiratory Syndrome Isolates and Methods of Use |
US8383131B2 (en) | 2004-09-21 | 2013-02-26 | Boehringer Ingelheim Vetmedica, Inc. | Porcine reproductive and respiratory syndrome isolates and methods of use |
US20090226486A1 (en) * | 2005-02-25 | 2009-09-10 | Pfizer Inc | N protein mutants of porcine reproductive and respiratory syndrome virus |
US20090130143A1 (en) * | 2005-02-25 | 2009-05-21 | Dongwan Yoo | N protein mutants of porcine reproductive and respiratory syndrome virus |
US8128937B2 (en) | 2005-02-25 | 2012-03-06 | Pfizer Inc. | N protein mutants of porcine reproductive and respiratory syndrome virus |
US7544362B1 (en) * | 2005-02-25 | 2009-06-09 | Pfizer Inc. | N protein mutants of porcine reproductive and respiratory syndrome virus |
US20100136051A1 (en) * | 2005-02-25 | 2010-06-03 | Pfizer Inc. | N Protein Muants of Porcine Reproductive and Respiratory Syndrome Virus |
US9080143B2 (en) | 2005-06-24 | 2015-07-14 | University Of Minnesota | PRRS viruses, infectious clones, mutants thereof, and method of use |
US7666585B2 (en) | 2007-06-15 | 2010-02-23 | Protatek International, Inc. | Construction of chimera PRRSV, compositions and vaccine preparations |
US20080311143A1 (en) * | 2007-06-15 | 2008-12-18 | Protatek International, Inc. | Construction of chimera prrsv, compositions and vaccine preparations |
US20110117129A1 (en) * | 2008-08-25 | 2011-05-19 | Boehringer Ingelheim Vetmedica, Inc. | Vaccine Against Highly Pathogenic Porcine Reproductive and Respiratory Syndrome (HP PRRS) |
US20110059126A1 (en) * | 2009-09-02 | 2011-03-10 | Boehringer Ingelheim Vetmedica, Inc. | Methods of reducing virucidal activity in pcv-2 compositions and pcv-2 compositions with an improved immunogenicity |
US9561270B2 (en) | 2009-09-02 | 2017-02-07 | Boehringer Ingelheim Vetmedica, Inc. | Methods of reducing virucidal activity in PCV-2 compositions and PCV-2 compositions with an improved immunogenicity |
US9944902B2 (en) | 2011-02-17 | 2018-04-17 | Boehringer Ingelheim Vetmedica Gmbh | Commercial scale process for production of PRRSV |
US8765142B2 (en) | 2011-02-17 | 2014-07-01 | Boehringer Ingelheim Vetmedica Gmbh | European PRRSV strain |
US10668144B2 (en) | 2011-02-17 | 2020-06-02 | Boehringer Ingelheim Vetmedica Gmbh | European PRRSV strain |
US10039821B2 (en) | 2011-02-17 | 2018-08-07 | Boehringer Ingelheim Vetmedica Gmbh | European PRRSV strain |
US9187731B2 (en) | 2011-07-29 | 2015-11-17 | Boehringer Ingelheim Vetmedica Gmbh | PRRS virus inducing type I interferon in susceptible cells |
US9315781B2 (en) | 2011-07-29 | 2016-04-19 | Boehringer Ingelheim Vetmedica Gmbh | Infectious CDNA clone of european PRRS virus and uses thereof |
US9579373B2 (en) | 2013-03-15 | 2017-02-28 | Boehringer Ingelheim Vetmedica, Inc. | Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use |
US10010601B2 (en) | 2013-12-20 | 2018-07-03 | Boehringer Ingelheim Vetmedica Gmbh | PRRS virus variant, European PRRS virus cDNA clone, and uses thereof |
US10639364B2 (en) | 2013-12-20 | 2020-05-05 | Boehringer Ingelheim Vetmedica Gmbh | PRRS virus variant, european PRRS virus cDNA clone, and uses thereof |
CN114395583A (en) * | 2021-11-01 | 2022-04-26 | 扬州大学 | cDNA clone of porcine reproductive and respiratory syndrome virus expressing secreted luciferase and construction method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2366072A1 (en) | 2000-09-14 |
US20060240041A1 (en) | 2006-10-26 |
JP2002537845A (en) | 2002-11-12 |
PL351486A1 (en) | 2003-04-22 |
JP3961222B2 (en) | 2007-08-22 |
US8790656B2 (en) | 2014-07-29 |
WO2000053787A9 (en) | 2012-04-26 |
CA2366072C (en) | 2007-07-10 |
EP1157121A1 (en) | 2001-11-28 |
WO2000053787A1 (en) | 2000-09-14 |
AU3198200A (en) | 2000-09-28 |
EP1157121B1 (en) | 2013-04-24 |
PL204373B1 (en) | 2010-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8790656B2 (en) | PRRSV vaccines | |
AU719991B2 (en) | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof | |
US7273617B2 (en) | Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof | |
EP1018557B1 (en) | Infectious cDNA clone of north american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof | |
AU754938B2 (en) | PRRSV antigenic sites identifying peptide sequences of PRRS virus for use in vaccines or diagnostic assays | |
US7122347B2 (en) | Chimeric Arterivirus-like particles | |
US20040213805A1 (en) | Deletions in arterivirus replicons | |
WO2002095040A1 (en) | Delections in arterivirus replicons | |
CA2424400C (en) | Adaptation sites of prrsv | |
Welch et al. | Construction and evaluation of genetically engineered replication-defective porcine reproductive and respiratory syndrome virus vaccine candidates | |
US20040224327A1 (en) | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof | |
MXPA99003967A (en) | Infectious clones of rna viruses and vaccines and diagnostic assays derived thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ID-LELYSTAD, INSTITUUT VOOR DIERHOUDERIJ EN DIERGE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MEULENBERG, JANNEKE;VERHEIJI, HELENE;REEL/FRAME:012592/0944;SIGNING DATES FROM 20010901 TO 20010911 |
|
AS | Assignment |
Owner name: BOEHRINGER INGELHEIM VETMEDICA GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ID-LELYSTAD, INSTITUUT VOOR DIERHOUDERIJ EN DIERGEZONDHEID B.V.;REEL/FRAME:015785/0487 Effective date: 20041011 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |